CHEMTRADE LOGISTICS INCOME FUND **2023 Annual Financial Statements**



Where to find it

	MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING	
	INDEPENDENT AUDITOR'S REPORT	2
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	-
	CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	8
	CONSOLIDATED STATEMENTS OF CHANGES IN UNITHOLDERS' EQUITY	Ç
	CONSOLIDATED STATEMENTS OF CASH FLOWS	10
Note 1	CORPORATE INFORMATION	1
Note 2	BASIS OF PREPARATION	1
Note 3	REPORTABLE SEGMENTS	18
Note 4	REVENUE	2
Note 5	SELLING AND ADMINISTRATIVE EXPENSES	2
Note 6	DEPRECIATION AND AMORTIZATION	2
Note 7	NET FINANCE COSTS	22
Note 8	INCOME TAXES	23
Note 9	NET EARNINGS PER UNIT	28
Note 10	CASH AND CASH EQUIVALENTS	29
Note 11	TRADE AND OTHER RECEIVABLES	29
Note 12	INVENTORIES	30
Note 13	PREPAID EXPENSES AND OTHER ASSETS	30
Note 14	DISPOSAL OF BUSINESS	3
Note 15	PROPERTY, PLANT AND EQUIPMENT	32
Note 16	LEASES	34
Note 17	INVESTMENT IN A JOINT VENTURE	36
Note 18	OTHER ASSETS	36
Note 19	INTANGIBLE ASSETS	37
Note 20	TRADE AND OTHER PAYABLES	38
Note 21	PROVISIONS	38
Note 22	LONG-TERM DEBT	40
Note 23	CONVERTIBLE UNSECURED SUBORDINATED DEBENTURES	4
Note 24	OTHER LONG-TERM LIABILITIES	42
Note 25	EMPLOYEE BENEFITS	43
Note 26	UNITS AND OTHER COMPONENTS OF EQUITY	47
Note 27	SHARE- BASED PAYMENTS	49
Note 28	COMMITMENTS AND CONTINGENCIES	5
Note 29	FINANCIAL INSTRUMENTS	52
Note 30	CAPITAL MANAGEMENT	6
Note 31	RELATED PARTIES	63
Note 32	MATERIAL ACCOUNTING POLICIES	6

MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING

The accompanying consolidated financial statements of Chemtrade Logistics Income Fund (the "Fund") and all the information in this annual report are the responsibility of the management of the Fund. The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and where appropriate include management's best estimates and judgements. Management has reviewed the financial information presented throughout this report and has ensured it is consistent with the consolidated financial statements.

Management has developed and maintains a system of internal control over financial reporting. These controls are designed to provide reasonable assurance that assets are safeguarded, transactions are accurately recorded and financial information is timely and reliable.

The Trustees of the Fund are responsible for ensuring that management fulfills its financial reporting responsibilities and are ultimately responsible for reviewing and approving the consolidated financial statements. The Trustees carry out this responsibility principally through the Audit Committee. The Audit Committee is comprised entirely of independent Trustees.

The Audit Committee meets periodically with management and the external auditors to discuss internal controls over financial reporting, policies and procedures, and financial reporting issues. Acting on the recommendation of the Audit Committee, the Trustees approve the consolidated financial statements. KPMG LLP, an independent firm of Chartered Professional Accountants, has been appointed by the Unitholders to express an independent professional opinion on the fairness of the consolidated financial statements. KPMG LLP has full and free access to the Audit Committee.

Scott Rook

President & Chief Executive Officer

Rohit Bhardwaj
Chief Financial Officer

Bloom

Toronto, Canada February 20, 2024

Statt Roll



INDEPENDENT AUDITOR'S REPORT

To the Unitholders' of Chemtrade Logistics Income Fund

Opinion

We have audited the consolidated financial statements of Chemtrade Logistics Income Fund (the Entity), which comprise:

- the consolidated statements of financial position as at December 31, 2023 and December 31, 2022
- the consolidated statements of comprehensive income for the years then ended
- the consolidated statements of changes in unitholders' equity for the years then ended
- · the consolidated statements of cash flows for the years then ended
- and notes to the consolidated financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the consolidated financial position of the Entity as at December 31, 2023 and December 31, 2022, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements for the year ended December 31, 2023. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



We have determined the matters described below to be the key audit matters to be communicated in our auditor's report.

Evaluation of impairment of goodwill

Description of the matter

We draw attention to Notes 2(d)(ii),19 and 32(i)(ii) to the financial statements. The Entity has recorded a goodwill balance of \$467,954 thousand. The Entity performs a goodwill impairment test on an annual basis or more frequently when events or changes in circumstances indicate that the carrying amount of a cash generating unit (CGU) or CGU group likely exceeds its recoverable amount. The recoverable amount of each CGU or CGU group is based on the higher of its value in use and its fair value less costs to sell. The Entity's significant estimates in determining its value in use include forecast operating margins, maintenance and other capital expenditures, terminal growth rates and discount rates.

Why the matter is a key audit matter

We identified the evaluation of impairment of goodwill as a key audit matter. This matter represented an area of significant risk of material misstatement due to the magnitude of the balance and the high degree of estimation uncertainty in determining the value in use. Significant auditor judgment and the involvement of those with specialized skills and knowledge were required in performing and evaluating the results of our procedures due to the sensitivity of the value in use to minor changes in certain significant estimates.

How the matter was addressed in the audit

The primary procedures we performed to address this key audit matter included the following on each CGU or CGU group with goodwill:

- We assessed the Entity's ability to accurately forecast by comparing the Entity's forecast operating margins and maintenance and other capital expenditures used in the prior year impairment test to actual results
- We compared the Entity's forecast operating margins and maintenance and other capital
 expenditures to the actual operating margins and maintenance and other capital
 expenditures. We took into account changes in conditions and events affecting each cash
 generating unit group with goodwill to assess the adjustments, or lack of adjustments, made
 in arriving at those forecast operating margins and maintenance and other capital
 expenditures.

We involved valuation professionals with specialized skills and knowledge, who assisted in:

- Comparing the Entity's terminal growth rates against long-term estimates of inflation in North America
- Comparing the Entity's discount rates against a discount rate that was independently developed using publicly available market data for comparable entities.



Other Information

Management is responsible for the other information. Other information comprises:

- the information included in Management's Discussion and Analysis filed with the relevant Canadian Securities Commissions.
- the information, other than the financial statements and the auditor's report thereon, included in a document likely to be entitled "2023 Annual Report".

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information included in Management's Discussion and Analysis filed with the relevant Canadian Securities Commissions as at the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.

The information, other than the financial statements and the auditor's report thereon, included in a document likely to be entitled "2023 Annual Report" is expected to be made available to us after the date of this auditor's report. If, based on the work we will perform on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis for our opinion.
 - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the
 disclosures, and whether the financial statements represent the underlying transactions and
 events in a manner that achieves fair presentation.



- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- Provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group Entity to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.
- Determine, from the matters communicated with those charged with governance, those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our auditor's report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

KPMG LLP

Chartered Professional Accountants, Licensed Public Accountants

The engagement partner on the audit resulting in this auditor's report is Laura Price.

Vaughan, Canada

February 20, 2024

Consolidated Statements of Comprehensive Income (In thousands of Canadian dollars, except per unit amounts)

	Year ended December 31,					
	Notes		2023		2022	
Revenue	4	\$	1,846,766	\$	1,813,383	
Cost of sales and services	6,12,15		(1,426,120)		(1,476,897)	
Gross profit			420,646		336,486	
Selling and administrative expenses	5		(128,190)		(134,316)	
Gain on disposal of assets	14,15		24,337		17,418	
Share of loss from joint venture	17		(1,413)		(436)	
Operating income			315,380		219,152	
Net finance costs	7		(24,008)		(49,969)	
Income before income tax			291,372		169,183	
Income tax expense	8					
Current			(14,689)		(11,958)	
Deferred			(27,364)		(48,110)	
			(42,053)		(60,068)	
Net earnings		\$	249,319	\$	109,115	
Other comprehensive income						
lance that many other manually be unclear; find to comin up.						
Items that may subsequently be reclassified to earnings: Net investment hedge of foreign operations, net of tax of						
(\$3,955) (2022 - net of tax of \$3,955)	22,29		(1,371)		(27,300)	
Foreign currency translation differences for foreign operations, net of tax of \$nil (2022 - \$nil)			(23,523)		60,577	
Effective portion of change in the fair value of cash flow hedges, net of tax of (\$20) (2022 - net of tax of (\$4,795))			59		14,156	
Cash flow hedges reclassified to earnings, net of tax of	-		(5.004)			
\$1,786 (2022 - net of tax of \$1,506)	7		(5,231)		(4,447)	
Items that will not be reclassified to earnings: Defined benefit plan adjustments, net of tax of (\$2,103) (2022)						
- net of tax of (\$492))	25		7,422		1,197	
Change in fair value of convertible debentures due to own credit risk, net of tax of \$1,621 (2022 - net of tax of						
\$3,893)	23		(28,329)		4,721	
Other comprehensive (loss) income			(50,973)		48,904	
Total comprehensive income		\$	198,346	\$	158,019	
Net earnings per unit	9					
Basic net earnings per unit		\$	2.15	\$	1.01	
Diluted net earnings per unit		\$	1.52	\$	0.99	

Consolidated Statements of Financial Position (In thousands of Canadian dollars)

	Notes	December 31, 2023	December 31, 2022
ASSETS			
Current assets			
Cash and cash equivalents	10	\$ 21,524	\$ 72,569
Trade and other receivables	11	146,686	123,214
Inventories	12	124,906	147,380
Income taxes receivable		7,925	5,434
Prepaid expenses and other assets	13	24,981	12,272
Total current assets		326,022	360,869
Non-current assets			
Property, plant and equipment	15	963,813	957,606
Right-of-use assets	16	165,043	127,603
Investment in a joint venture	17	4,082	5,495
Income taxes receivable	8	48,381	_
Other assets	18	13,572	36,334
Intangible assets	19	538,615	586,455
Deferred tax assets	8	49,704	82,711
Total non-current assets		1,783,210	1,796,204
Total assets		\$ 2,109,232	\$ 2,157,073
LIABILITIES AND UNITHOLDERS' EQUITY			
Current liabilities			
Trade and other payables	20	\$ 299,351	\$ 316,437
Distributions payable	26	5,884	5,805
Provisions	21	55,285	22,822
Lease liabilities	16	49,304	45,571
Total current liabilities		409,824	390,635
Non-current liabilities			
Long-term debt	22	246,545	370,024
Convertible unsecured subordinated debentures	23	437,517	533,218
Other long-term liabilities	24	23,228	21,571
Long-term lease liabilities	16	130,583	94,071
Employee benefits	25	20,491	27,555
Provisions	21	118,681	135,626
Deferred tax liabilities	8	15,222	18,166
Total non-current liabilities		992,267	1,200,231
Total liabilities		1,402,091	1,590,866
Unitholders' equity			
Units	26	1,648,411	1,635,683
Contributed surplus		9,720	9,720
Deficit		(1,147,923)	(1,334,524)
Accumulated other comprehensive income		196,933	255,328
Total unitholders' equity		707,141	566,207
			000,=01

For commitment and contingencies, see Note 28

On behalf of the Board of Trustee

Douglas Muzyka Daniella Dimitrov

Consolidated Statements of Changes in Unitholders' Equity (In thousands of Canadian dollars, except per unit amounts)

	Notes	Units	Co	ntributed surplus	Deficit	Cumulative translation account*	Unrealized losses (gains) on cash flow and net investment hedges*	Change in fair value of convertible debentures due to credit risk*		Total nitholders' equity
Balance at January 1, 2022		\$ 1,541,583	\$	9,720 \$	(1,379,076)	\$ 157,393	\$ 13,329	\$ 36,899	\$	379,848
Issuance of units for cash, net of transaction costs Issuance of units under the	26	83,666		_	_	_	_	_		83,666
Distribution Reinvestment Plan ("DRIP")	26	10,434		_	_	_	_	_		10,434
Net earnings		_		_	109,115	_	_	_		109,115
Other comprehensive income (loss)		_		_	1,197	60,577	(17,591)	4,721		48,904
Distributions	26	_		_	(65,760)	_	_	_		(65,760)
Balance at December 31, 2022		\$ 1,635,683	\$	9,720 \$	(1,334,524)	\$ 217,970	\$ (4,262)	\$ 41,620	\$	566,207
Issuance of units upon conversion of unsecured subordinated convertible debentures	23,26	698		_	_	_	_	_		698
Issuance of units under the DRIP	26	12,030		_	_	_	_	_		12,030
Net earnings		_		_	249,319	_	_	_		249,319
Other comprehensive income (loss)		_		_	7,422	(23,523)	(6,543)	(28,329))	(50,973)
Distributions	26			_	(70,140)	_	_	_		(70,140)
Balance at December 31, 2023		\$ 1,648,411	\$	9,720 \$	(1,147,923)	\$ 194,447	\$ (10,805)	\$ 13,291	\$	707,141

^{*} Accumulated other comprehensive income.

Consolidated Statements of Cash Flows (In thousands of Canadian dollars)

		Year ended [December 31,
	Notes	2023	2022
Cash flows from operating activities:			
Net earnings		\$ 249,319	\$ 109,115
Adjustments for:		, ,	, ,,,,,,,
Depreciation and amortization	6	217,490	216,950
Net (gain) loss on disposal and write-down of property, plant and equipment ("PPE")		(2,002)	2,592
Change in environmental and decommissioning liability	21	7,232	_
Gain on disposal of assets	14,15	(24,337)	(17,418)
Income tax expense	8	42,053	60,068
Net finance costs	7	24,008	49,969
Unrealized foreign exchange (gain) loss	5	(11,126)	9,592
		502,637	430,868
(Increase) decrease in working capital		(16)	5,989
Interest paid		(44,294)	(53,407)
Interest received		6,352	2,395
Net income tax paid		(63,216)	(16,654)
Net cash flows from operating activities		401,463	369,191
Cash flows from investing activities: Capital expenditures Net proceeds from disposal of assets Investment in a joint venture	15 14 17	(166,395) 47,939 —	(115,440) 12,494 (5,931)
Net cash flows used in investing activities		(118,456)	(108,877)
Cash flows from financing activities:			
Distributions to unitholders, net of distributions reinvested	26	(58,031)	
Repayment of convertible debentures	23	(201,115)	
Issuance of units	26	_	86,543
Transaction costs related to the issuance of units	26		(4,091)
Issuance of convertible debentures	23	110,000	_
Transaction costs related to the issuance of convertible debentures	7,23	(4,980)	
Repayment of lease liability, net of sub-lease receipts	16	(58,256)	(52,360)
Net change in revolving credit facility	22	(121,149)	(34,593)
Net cash flows used in financing activities		(333,531)	(203,004)
(Decrease) increase in cash and cash equivalents		(50,524)	57,310
Cash and cash equivalents, beginning of the period		72,569	13,908
Effect of exchange rates on cash held in foreign currencies		(521)	1,351
Cash and cash equivalents, end of the period	10	\$ 21,524	\$ 72,569

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

1. CORPORATE INFORMATION:

Chemtrade Logistics Income Fund (the "Fund") is a publicly listed Income Trust formed in Ontario, Canada and its units are listed on the Toronto Stock Exchange ("TSX"). The term "Chemtrade" refers to the Fund, its consolidated subsidiaries and equity accounted investments, including joint ventures. Chemtrade commenced operations on July 18, 2001 when it completed an initial public offering. Chemtrade operates a diversified business providing industrial chemicals and services to customers in North America and around the world. Chemtrade is one of North America's largest suppliers of sulphuric acid, spent acid processing services, inorganic coagulants for water treatment, sodium chlorate, sodium nitrite and sodium hydrosulphite. Until November 8, 2023, Chemtrade also manufactured phosphorus pentasulphide (P₂S₅), see note 14. Chemtrade is a leading regional supplier of sulphur, chloralkali products and zinc oxide. Additionally, Chemtrade provides industrial services such as processing by-products and waste streams. Chemtrade operates in two reportable segments: Sulphur and Water Chemicals ("SWC") and Electrochemicals ("EC"). In addition to the above two reportable segments, Chemtrade discloses results of corporate activities separately. For additional information regarding Chemtrade's reportable segments, see note 3.

Chemtrade is an entity domiciled in Canada. The head office, principal address, and registered and records office of the Fund are located at 155 Gordon Baker Road, Suite 300, Toronto, Ontario, M2H 3N5.

Chemtrade's consolidated financial statements include all of its controlled subsidiaries and equity accounted investments and have been prepared on a going concern basis, which contemplates the realization of assets and settlements of liabilities in the normal course of business.

2. BASIS OF PREPARATION:

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with IFRS Accounting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These consolidated financial statements were authorized for issue by the Board of Trustees ("Board") on February 20, 2024.

(b) Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis, except for the following material items in the consolidated statements of financial position:

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

2. BASIS OF PREPARATION (continued):

- Derivative financial instruments, convertible unsecured subordinated debentures (the "Debentures") and liabilities for cash settled share-based payment arrangements are measured at fair value;
- The defined benefit liability is recognized as the present value of the defined benefit obligation net of the fair value of the plan assets; and
- Deferred tax assets and liabilities are measured at the tax rates that are expected to be applied to temporary differences when they reverse.

(c) Presentation currency

These consolidated financial statements are presented in thousands of Canadian dollars, except for net earnings per unit information, per metric electrochemical unit ("MECU") information and per tonne information which is presented in Canadian dollars.

(d) Significant judgments and sources of estimation uncertainty

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

(i) Significant judgments

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements is included in the following notes:

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

2. BASIS OF PREPARATION (continued):

Income taxes (note 8):

In the normal course of operations, judgment is required in assessing tax interpretations, regulations and legislation and in determining the provision for income taxes, deferred tax assets and liabilities, and the timing of reversals. Chemtrade makes judgments to evaluate whether it can recover a deferred tax asset based on its assessment of many factors, including interpretations of tax laws, expectation about the future taxable profit probability level, and the timing and reversal of temporary differences. To the extent that a recognition or de-recognition of a deferred tax asset is required, current period earnings or other comprehensive income will be affected.

Leases (note 16):

Chemtrade estimates the lease term by considering the facts and circumstances that can create an economic incentive to exercise an extension option, or not exercise a termination option. Chemtrade makes certain qualitative and quantitative assumptions when deriving the value of the economic incentive.

Investment in a joint venture (note 17):

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control. Chemtrade applies judgment in determining whether it has joint control of the joint venture.

Intangible assets (note 19):

Judgment is applied in determining cash-generating units ("CGUs") for the purpose of impairment testing.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

2. BASIS OF PREPARATION (continued):

Provisions (note 21):

Chemtrade recognizes provisions for the present value of anticipated costs of future decommissioning and environmental liabilities. Chemtrade applies judgment in determining whether it has a present obligation (legal or constructive) as a result of a past event, whether it is probable ("more likely than not") that an outflow of economic resources would be required to settle the obligation and whether the amount can be estimated reliably.

Chemtrade is subject to litigation in the normal course of business. Chemtrade has made judgments as to the likelihood of any claim succeeding in recording provisions.

Financial instruments (note 29):

Chemtrade makes significant judgments in determining whether its financial instruments qualify for hedge accounting, including its determination of hedge effectiveness. These judgments include assessing whether the forecast transactions designated as hedged items in hedging relationships will materialize as forecast, whether the hedging relationships designated as effective hedges for accounting purposes continue to qualitatively be effective.

(ii) Key sources of estimation uncertainty

Information about assumptions and estimation uncertainty that have a significant risk of resulting in a material adjustment within the next financial year are included in the following notes:

Property, plant and equipment (note 15):

Parts of an item of PPE may have different useful lives. Chemtrade makes significant estimates when determining depreciation rates and asset useful lives, which require taking into account company-specific factors, such as its past experience and expected use, and industry trends, such as technological advancements. Depreciation methods, useful lives and residual values are reviewed at each financial year end and adjusted if appropriate.

Notes to Consolidated Financial Statements
(In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

2. BASIS OF PREPARATION (continued):

Leases (note 16):

Right-of-use ("ROU") assets are measured at the initial amount of the lease liabilities plus any initial direct costs, lease payments made at or before the commencement date net of lease incentives received, and decommissioning costs. Chemtrade estimates the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Chemtrade's incremental borrowing rate, to measure the lease liability.

Intangible assets (note 19):

When determining the value in use of goodwill and intangible assets during impairment testing, Chemtrade uses the following significant estimates: forecast operating margins, maintenance and other capital expenditures, terminal growth rates and discount rates. If actual results differ or a change in expectation arises, an impairment charge may be required.

Chemtrade makes significant estimates when determining the estimated useful lives of intangible assets, which require taking into account company-specific factors, such as its past experience and expected use, and industry trends, such as technological advancements. Amortization methods, useful lives and residual values are reviewed at each financial year end and adjusted if appropriate.

Provisions (note 21):

Provisions have been recorded based on the present value of anticipated costs for future decommissioning and environmental liabilities. Decommissioning liabilities include future cost estimates of statutory, contractual, constructive or legal obligations associated with the decommissioning of Chemtrade's plants. Environmental liabilities are recorded based on the current interpretation of environmental laws and regulations when it is probable that a liability has been incurred and the amount of such a liability can be reliably estimated.

Cash outflows associated with these provisions are generally expected to occur at future dates and are long-term in nature. The calculation of these provisions requires assumptions such as the discount rate and cost estimates. The provisions recognized are periodically reviewed and updated based on the facts and circumstances available at the time.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

2. BASIS OF PREPARATION (continued):

Provisions for legal claims are recognized when a past event creates a legal or constructive obligation that can be reasonably estimated and is likely to result in an outflow of economic resources. Significant estimates are involved in estimating the present value of the expenditure expected to settle obligations.

The time of concluding legal claims is uncertain, as is the amount of possible outflow of economic resources. Timing and cost ultimately depends on the due process in respective legal jurisdictions. Provisions recognized by Chemtrade are periodically reviewed based on facts and circumstances available at the time.

Employee Benefits (note 25):

Significant estimates are involved in determining defined benefit obligations. The calculation of the liabilities related to pension plans is based upon statistical and actuarial assumptions. Certain pension plans are frozen for future benefit accruals and the pension benefits are not indexed to inflation. These pension plans are comprised primarily of inactive and retired participants and the actuarial estimates of pension benefits are affected by the amount of time retirees are expected to receive their pensions (mortality assumptions) and the interest rate used to discount the expected future benefit payments (discount rate assumption). The actuarial estimates of other pension plans are also based on projections of employees' compensation levels at their expected time of retirement. These retirement benefits are primarily based on final average earnings, subject to certain adjustments.

The actuarial assumptions used might differ materially from actual results due to changes in market and economic conditions, higher or lower employee turnover, longer or shorter life spans of participants, and other changes in the factors being assessed. These differences could impact the assets or liabilities recognized in the consolidated statements of financial position in future periods.

Chemtrade obtains actuarial valuations for its post employment benefit plans.

Share-based payments (note 27):

Chemtrade makes significant estimates to determine the fair value of cash settled share-based payments, Long-Term Incentive Plan ("LTIP") and deferred unit plan ("DUP"). Determining the fair value of the cash settled share-based payments, including performance based options, requires significant estimates related to the estimation of unit price, volatility, expected market conditions and future financial performance of the Fund.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

2. BASIS OF PREPARATION (continued):

Financial instruments (note 29):

Fair value estimates related to Chemtrade's derivatives and convertible unsecured subordinated debentures are made at each reporting period based on relevant market information and information about the underlying financial instruments. These estimates require assessment of the credit risk of the parties to the instruments and the instruments' discount rates.

(e) Reclassification of prior period presentation

A gain on sale of assets recorded in 2022 has been reclassified from cost of sales and services to a separate line item to conform to current period's presentation. See note 15 for details of the disposition.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

3. REPORTABLE SEGMENTS:

Chemtrade operates in two reportable segments: Sulphur and Water Chemicals ("SWC") and Electrochemicals ("EC"). The reportable segments of Chemtrade are strategic business groups that offer products and services to target markets.

Chemtrade's chief operating decision maker ("CODM") is the Chief Executive Officer ("CEO"). The CODM regularly reviews the operations and performance by segment and considers Adjusted EBITDA as an indirect measure of net earnings (loss) for the purpose of assessing performance of each segment and to make decisions about the allocation of resources. Adjusted EBITDA is defined as net earnings before any deduction for net finance costs, income taxes, depreciation, amortization and other non-cash charges such as impairment, change in environmental and decommissioning liability, net gain and losses on the disposal and write-down of PPE, gain on disposal of assets and unrealized foreign exchange gains and losses. Adjusted EBITDA is not intended to be representative of cash flow from operations or financial performance determined in accordance with IFRS or cash available for distribution. The remaining net earnings (loss) items and the Statements of Financial Position are reviewed on a consolidated basis by the CODM and therefore are not included in the segmented information below.

Year ended December 31, 2023

			Corporate items and	
	SWC	EC	eliminations	Total
Revenue - third party	\$1,077,157	\$ 769,609	\$ —	\$ 1,846,766
- inter-segment	196	7,735	(7,931)	_
Revenue - total	1,077,353	777,344	(7,931)	1,846,766
Cost of sales and services	(925,062)	(508,989)	7,931	(1,426,120)
Gross profit	152,291	268,355	_	420,646
Selling and administrative expenses	(25,227)	(12,797)	(90,166)	(128,190)
Gain on disposal of assets (1)	24,337	_	_	24,337
Share of loss from joint venture	(1,413)	_	_	(1,413)
Operating income (loss)	149,988	255,558	(90,166)	315,380
Depreciation and amortization	123,563	93,927	_	217,490
Net gain on disposal and write-down of PPE	(1,972)	(30)	_	(2,002)
Gain on disposal of assets (1)	(24,337)	_	_	(24,337)
Change in environmental and decommissioning liability	5,929	1,303	_	7,232
Unrealized foreign exchange gain	_	_	(11,126)	(11,126)
Adjusted EBITDA	253,171	350,758	(101,292)	502,637
Capital expenditures	120,859	43,889	1,647	166,395

⁽¹⁾ For additional information, see note 14.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

3. REPORTABLE SEGMENTS (continued):

Year ended December 31, 2022

Year ended December 31, 2022			Corporate items and	
	SWC	EC	eliminations	Total
Revenue - third party	\$1,074,732	\$ 738,651	\$ —	\$ 1,813,383
- inter-segment	485	5,639	(6,124)	_
Revenue - total	1,075,217	744,290	(6,124)	1,813,383
Cost of sales and services	(926,168)	(556,853)	6,124	(1,476,897)
Gross profit	149,049	187,437	_	336,486
Selling and administrative expenses	(19,100)	(9,875)	(105,341)	(134,316)
Gain on disposal of assets (1)	17,418	_	_	17,418
Share of loss from joint venture	(436)	_	_	(436)
Operating income (loss)	146,931	177,562	(105,341)	219,152
Depreciation and amortization	112,135	104,815	_	216,950
Gain on disposal of assets (1)	(17,418)	_	_	(17,418)
Net loss on disposal and write-down of PPE	2,176	416	_	2,592
Unrealized foreign exchange loss	_	_	9,592	9,592
Adjusted EBITDA	243,824	282,793	(95,749)	430,868
Capital expenditures	69,935	42,862	2,643	115,440

⁽¹⁾ For additional information, see note 15.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

3. **REPORTABLE SEGMENTS** (continued):

Geographic segments:

Chemtrade operates primarily in Canada, the United States and South America. Revenue is attributed to customers based on location of sale.

Revenue

	2023	2022
Canada	\$ 582,073	\$ 584,095
United States	1,158,846	1,127,152
South America	105,847	102,136
	\$ 1,846,766	\$ 1,813,383

PPE, ROU assets and intangible assets

	De	ecember 31, 2023	[December 31, 2022
Canada	\$	740,495	\$	748,519
United States		840,051		823,078
South America		86,925		100,067
	\$	1,667,471	\$	1,671,664

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

4. REVENUE:

The components of revenue are as follows:

	2023	2022
Sale of products	\$1,620,896	\$1,611,712
Processing services	225,870	201,671
Revenue	\$1,846,766	\$1,813,383

5. SELLING AND ADMINISTRATIVE EXPENSES:

The components of selling and administrative expenses are as follows:

	2023	2022
Wages, salaries and benefits, including bonuses	\$ 74,527	\$ 62,983
Share-based payments (note 27)	17,332	20,971
Other selling and administrative expenses	44,334	34,917
Realized foreign exchange (gain) loss	(1,629)	2,484
Unrealized foreign exchange (gain) loss	(11,126)	9,592
Reserve for legal proceedings	3,182	922
Depreciation (note 6)	1,570	2,447
	\$ 128,190	\$ 134,316

6. DEPRECIATION AND AMORTIZATION:

The components of depreciation expense of PPE and ROU assets and amortization expense of intangible assets are as follows:

	2023	2022
Cost of sales and services:		
Depreciation expense on PPE (note 15)	\$ 128,745	\$ 127,868
Depreciation expense on ROU assets (note 16)	48,647	45,174
Amortization expense (note 19)	38,528	41,461
Selling and administrative expenses (note 5):		
Depreciation expense on PPE (note 15)	554	1,216
Depreciation expense on ROU assets (note 16)	1,016	1,231
Total depreciation and amortization expense	\$ 217,490	\$ 216,950

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

7. NET FINANCE COSTS:

The components of net finance costs are as follows:

	2023	2022
Interest expense on long-term debt	\$ 12,085	\$ 21,362
Interest expense on convertible debentures (note 23)	32,200	32,004
Transaction costs on issuance of convertible debentures (note 23)	4,980	_
Change in the fair value of convertible debentures (note 23)	(33,838)	7,623
Interest expense on lease liabilities (note 16)	7,771	5,893
Income reclassified from other comprehensive income relating to the fair value of the interest rate swaps (note 29)	(7,017)	(5,953)
Change in the fair value of interest rate swaps (note 29)	10,181	(10,692)
Ineffective portion of change in the fair value of interest rate swaps	_	(1,466)
Accretion of provisions (note 21)	2,483	2,892
Pension interest (note 25)	1,515	701
Interest income	(6,352)	(2,395)
Net finance costs	\$ 24,008	\$ 49,969

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

8. INCOME TAXES:

The Fund is a mutual fund trust and a specified investment flow-through trust ("SIFT") for income tax purposes. The Fund is subject to current income taxes at the top marginal tax rate applicable to individuals of approximately 53.5% on all taxable income not distributed to Unitholders.

The Fund is also subject to current income taxes on all taxable income, other than dividends, earned from Canadian corporate and flow-through subsidiaries (other than Canadian subsidiaries that earn certain investment income) at a tax rate similar to the corporate tax rate.

The Fund will not be subject to tax on income received from non-Canadian subsidiaries, provided that the income is distributed to Unitholders during the year. Based on the current organization of Chemtrade, the Fund expects that its income distributed to Unitholders will not be subject to SIFT tax.

(a) Income tax expense

	2023	2022
Taxes recognized in net earnings	14,689	11,958
Current tax expense	14,689	11,958
Deferred tax expense (recovery): Origination and reversal of temporary differences Changes in recognition of tax losses and deductible temporary differences	48,359 (20,995)	16,865 31,245
Deferred tax expense	27,364	48,110
Total tax expense	42,053	60,068

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

8. INCOME TAXES (continued):

(b) Reconciliation of the effective tax rate

The provision for income taxes in comprehensive income represents an effective rate different than the Canadian corporate statutory rate of 25.15% (2022 - 25.31%). The differences are as follows:

	2023	2022 (1)
Net income before income tax	\$ 291,372	\$ 169,183
Computed income tax expense at Canadian statutory rate	73,280	42,820
Difference resulting from:		
Income of trust taxed directly to unitholders	(28,299)	(22,541)
Difference in applicable domestic tax rate	16,987	11,547
International income tax differences	2,665	1,398
Tax adjustments related to prior years	2,238	1,073
Impact of tax incentives	(4,994)	(5,032)
Disposal of assets (note 14)	(694)	_
Changes in recognition of tax losses and deductible temporary differences $^{(2)}$	(20,995)	31,245
Other, including non-taxable and non-deductible items	1,865	(442)
Total income tax expense	\$ 42,053	\$ 60,068

⁽¹⁾ Certain prior year amounts have been regrouped to conform to the current year's presentation.

⁽²⁾ For 2023, this amount primarily related to utilization of previously unrecognized tax losses. For 2022, this amount is primarily related to the derecognition of deferred tax assets related to certain business interest amounts that are subject to limited deductibility under current tax legislation.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

8. **INCOME TAXES** (continued):

(c) Recognized deferred tax assets and liabilities

Recognized deferred tax assets and liabilities are attributed to the following:

	2023	2022 (1)
Deferred tax assets:		
Other assets	\$ 49,208 \$	56,991
Losses available for carryforward	25,072	70,153
Long-term debt and deferred interest	23,947	27,273
Other long-term liabilities and employee benefits	45,434	40,681
	143,661	195,098
Reclassification from deferred tax liabilities	(93,957)	(112,387)
Total deferred tax assets	\$ 49,704 \$	82,711
Deferred tax liabilities:		
PPE	96,670	109,430
Intangible assets	8,743	14,200
3	•	•
Other liabilities	3,766	6,923
	109,179	130,553
Reclassification to deferred tax assets	(93,957)	(112,387)
Total deferred tax liabilities	\$ 15,222 \$	18,166

⁽¹⁾ Certain prior year amounts have been regrouped to conform to the current year's presentation.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

8. **INCOME TAXES** (continued):

(d) Movements in deferred tax balances

Movements in deferred tax balances during the year are as follows:

	Balance January 1, 2023	Recognize in ne earning	t	Foreign exchange rate changes	Recognized in other comprehensive income	Recognized directly in equity	Balance December 31, 2023
PPE	\$ (109,430) \$	10,87	2 \$	1,888	\$ - \$	—	\$ (96,670)
Intangible assets	(14,200)	5,19	5	262	_	_	(8,743)
Net other assets and liabilities	50,068	(2,48	3)	(1,520)	(618)	_	45,442
Losses available for carryforward	70,153	(44,90	5)	(176)	_	_	25,072
Long-term debt and deferred interest	27,273	(2,93))	(396)	_	_	23,947
Other long-term liabilities and employee benefits	40,681	6,89	2	(86)	(2,053)	_	45,434
	\$ 64,545 \$	(27,36	1) \$	(28)	\$ (2,671) \$	<u> </u>	\$ 34,482

		Balance January 1, 2022 ⁽¹⁾	Recognized in net earnings ⁽¹⁾	Foreign exchange rate changes	Recognized in other comprehensive income	Recognized directly in equity	Balance December 31, 2022 ⁽¹⁾
	_					_	•
PPE	\$	(138,277) \$	34,214 \$	(5,367)	\$ —	\$ —	\$ (109,430)
Intangible assets		(18,387)	5,554	(1,367)	_	_	(14,200)
Net other assets and liabilities		53,367	(6,736)	(456)	3,893	_	50,068
Losses available for carryforward Long-term debt and deferred		127,588	(58,300)	865	_	_	70,153
interest		43,948	(20,824)	2,936	_	1,213	27,273
Other long-term liabilities and employee benefits		38,102	(2,018)	4,423	174	_	40,681
	\$	106,341 \$	(48,110) \$	1,034	\$ 4,067	\$ 1,213	\$ 64,545

 $^{^{(1)}}$ Certain prior year amounts have been regrouped to conform to the current year's presentation.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

8. **INCOME TAXES** (continued):

(e) Unrecognized deferred tax assets

For the year ended December 31, 2023, Chemtrade did not recognize \$42,764 (2022 - \$65,064) of deferred tax assets primarily related to unused tax losses that are capital in nature and deductible temporary differences on certain carryforward amounts of business interest expense deductions. Chemtrade did not recognize the deferred tax assets as management did not believe it is probable that sufficient future taxable profit will be available against which these unused tax losses and deductible temporary differences can be utilized. The unused tax losses can be carried forward indefinitely. The deductible temporary differences do not expire under current applicable tax legislation.

(f) Tax examinations and disputes

Chemtrade is subject to challenges from various tax authorities on an ongoing basis. As a result, from time to time, tax authorities may disagree with the positions and conclusions taken by Chemtrade in its tax filings or legislation could be amended or interpretations of current legislation could change, any of which events could lead to assessments of additional amounts of tax, interest and possibly penalties. Chemtrade accrues and accounts for any probable assessments of tax; however, there can be no assurance as to the final resolution of any tax authority positions.

Chemtrade is disputing the deductibility of certain Canadian tax losses with the Canada Revenue Agency ("CRA") which would offset the taxes owed for 2021, 2022 and 2023. Chemtrade has appealed this assessment by the CRA and the resolution of this matter in Chemtrade's favour would result in significant taxes paid on its account to be refunded.

Chemtrade made Canadian income tax payments of \$45,142 and \$3,239 during 2023 and 2022, respectively, relating to the 2021, 2022 and 2023 taxation years. Chemtrade believes that its asserted position is appropriate and would be sustained upon full examination by tax authorities and, if necessary, upon consideration by judicial process. These payments have been presented as income taxes receivable in the Consolidated Statements of Financial Position.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

8. **INCOME TAXES** (continued):

(g) Pillar Two Top-up Tax - Global Minimum Tax

Chemtrade has key operations in Canada, US, and Brazil. As of December 31, 2023, the Pillar Two Global Minimum Tax legislation has not been enacted or substantively enacted in any of the key jurisdictions in which Chemtrade operates. Draft legislation has been released in Canada and if enacted, will be effective for Chemtrade's fiscal years commencing January 1, 2024.

Chemtrade has carried out an assessment of potential impacts based on currently available information and currently does not expect any impact of significance from Pillar Two Global Minimum Tax proposals. Chemtrade will continue to monitor the implementation of, and changes in, Pillar Two Global Minimum Tax legislation in jurisdictions relevant to Chemtrade, and will assess additional impacts, if any.

While Chemtrade does not expect Pillar Two Global Minimum Tax to impact it, a temporary mandatory relief from deferred tax accounting for the future tax impacts of top-up tax is currently applicable. Accordingly, Chemtrade would account for top-up tax as a current tax when it is incurred.

9. NET EARNINGS PER UNIT:

Net earnings per unit has been calculated on the basis of the weighted average number of units outstanding. The following tables provide a breakdown of the numerator and denominator used in the calculation of net earnings per unit and diluted net earnings per unit:

	2023	2022
Numerator		
Net earnings	249,319	\$ 109,115
Net interest and fair value adjustment on the Debentures	(9,072)	36,631
Net fair value adjustment on deferred unit plan (1)	154	_
Diluted net earnings	\$ 240,401	\$ 145,746

⁽¹⁾ For the year ended December 31, 2022, the potential conversion of the deferred units have not been included as the effect on net earnings per unit would be anti-dilutive.

	2023	2022
Denominator		
Weighted average number of units	116,212,199	108,445,732
Weighted average Debentures dilutive units	41,146,814	38,960,721
Weighted average deferred unit plan dilutive units (1)	589,567	<u> </u>
Weighted average number of diluted units	157,948,580	147,406,452

⁽¹⁾ For the year ended December 31, 2022, the potential conversion of the deferred units have not been included as the effect on net earnings per unit would be anti-dilutive.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

10. CASH AND CASH EQUIVALENTS:

The components of cash and cash equivalents are as follows:

	2023	2022
Cash	\$ 1,985	\$ 16,555
Cash equivalents		
Guaranteed investment certificates	_	40,000
Certificate of deposits	19,539	16,014
Total cash and cash equivalents	\$ 21,524	\$ 72,569

11. TRADE AND OTHER RECEIVABLES:

	2023	2022
Trade and other receivables before expected credit losses	\$ 147,670	\$ 124,198
Less: expected credit losses	(984)	(984)
Trade and other receivables	\$ 146,686	\$ 123,214

As disclosed in note 29, Chemtrade is exposed to normal credit and currency risks with respect to its accounts receivable. At December 31, 2023, 95.8% (2022 - 94.2%) of accounts receivable are less than 30 days past due, and less than 1% (2022 - less than 1%) of accounts receivable are greater than 120 days past due that are not provided for.

While Chemtrade evaluates a customer's credit worthiness before credit is extended, provisions for expected credit losses are also maintained. The change in allowance for expected credit losses are as follows:

	2023	2022
Balance at beginning of year	\$ 984	\$ 741
Adjustments made during the year	_	93
Recovery	_	150
Balance at end of year	\$ 984	\$ 984

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

11. TRADE AND OTHER RECEIVABLES (continued):

Receivables Purchase Facility

Chemtrade has a factoring facility of up to \$100,000 (the "A/R Facility") with HSBC Bank Canada. The A/R Facility is an uncommitted receivables purchase facility for the purchase of eligible receivables owed to Chemtrade from trade debtors on an undisclosed basis with no recourse. As at December 31, 2023, trade receivables sold under the A/R Facility were \$33,865 (2022 - \$42,706).

12. INVENTORIES:

Chemtrade's inventories are as follows:

	2023	2022
Raw materials	\$ 48,429	\$ 67,702
Finished goods	41,328	46,247
Operating supplies	35,149	33,431
Total inventories	\$ 124,906	\$ 147,380

The amount of inventories recognized as an expense in cost of sales and services during the year ended December 31, 2023 was \$1,094,197 (2022 - \$1,156,674).

13. PREPAID EXPENSES AND OTHER ASSETS:

Chemtrade's prepaid expenses and other assets are as follows:

	2023	2022
Prepaid expenses	\$ 8,418	\$ 7,889
Interest rate swaps (note 29)	10,886	_
Cash-settled unit swaps (note 29)	3,194	4,383
Foreign exchange contracts (note 29)	2,483	_
Total Prepaid expenses and other assets	\$ 24,981	\$ 12,272

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

14. DISPOSAL OF BUSINESS:

On November 8, 2023, Chemtrade completed the sale of its P_2S_5 business which was included in the SWC segment before, for gross proceeds of US\$43,018 (\$58,862), which consisted of cash of approximately US\$39,418 (\$53,936) and the assumption of Indebtedness (as defined in the sales agreement) of approximately US\$3,600 (\$4,926). After deducting a net working capital adjustment of approximately US\$1,020 (\$1,352), Chemtrade recorded a gain of US\$14,620 (\$20,082). Chemtrade also reclassified the cumulative amount of foreign exchange difference of \$4,255 recognized from AOCI to net earnings. Combined, the total gain on disposal recorded was \$24,337. Chemtrade recorded total taxes of \$4,021 on the sale of its P_2S_5 business.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

15. PROPERTY, PLANT AND EQUIPMENT:

Chemtrade's property, plant and equipment are as follows:

	Land	Plant and equipment	Facilities and equipment under construction	Total
Cost				
Balance at January 1, 2022	\$ 88,560 \$	1,871,545 \$	96,268 \$	2,056,373
Additions			115,440	115,440
Decommissioning provisions	_	(6,124)	_	(6,124)
Transfers	_	73,203	(73,203)	
Asset retirements and write-downs	_	(12,848)	_	(12,848)
Foreign exchange rate changes	2,356	79,097	6,113	87,566
Balance at December 31, 2022	\$ 90,916 \$	2,004,873 \$	144,618 \$	2,240,407
Additions	_	_	166,395	166,395
Disposals (note 14)	_	(36,368)	(2,068)	(38,436)
Decommissioning provisions	_	(8,532)	_	(8,532)
Transfers	_	124,506	(124,506)	_
Asset retirements and write-downs	_	(33,388)		(33,388)
Foreign exchange rate changes	(2,102)	(21,061)	(2,965)	(26,128)
Balance at December 31, 2023	\$ 88,814 \$	2,030,030 \$	181,474 \$	2,300,318
Accumulated depreciation				
Balance at January 1, 2022	\$ — \$	(1,115,799) \$	- \$	(1,115,799)
Depreciation	_	(129,084)	_	(129,084)
Asset retirements and write-downs	_	12,709	_	12,709
Foreign exchange rate changes	_	(50,604)	_	(50,604)
Depreciation allocated to inventory		(23)	_	(23)
Balance at December 31, 2022	\$ 	(1,282,801) \$	- \$	(1,282,801)
Depreciation	_	(129,299)	_	(129,299)
Asset retirements and write-downs	_	30,156	_	30,156
Disposals (note 14)	_	28,738	_	28,738
Foreign exchange rate changes	_	16,923	_	16,923
Depreciation allocated to inventory		(222)		(222)
Balance at December 31, 2023	\$ _ \$	(1,336,505) \$	<u> </u>	(1,336,505)
Net carrying amount				
December 31, 2022	\$ 90,916 \$	722,072 \$	144,618 \$	957,606
December 31, 2023	\$ 88,814 \$	693,525 \$	181,474 \$	963,813

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

15. PROPERTY, PLANT AND EQUIPMENT (continued):

On April 4, 2022, Chemtrade completed the sale of an idled acid plant in Augusta, GA. The details of the sale are as follows:

	To	otal
Net cash proceeds (US\$9,985)	\$ 12,4	94
Non-cash proceeds (1) - Acid supply contract (US\$1,362)	1,7	62
- Fair value of buildings to be completed in the future (US\$2,502)	3,2	236
Total proceeds (US\$13,849)	17,4	92
Net carrying amount of PPE sold (US\$58)	((74)
Gain on sale (US\$13,791)	\$ 17,4	18

⁽¹⁾ Non-cash proceeds are included in Other assets in the Consolidated Statement of Financial Position as at December 31, 2023 and December 31, 2022.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

16. LEASES:

(i) ROU assets

Chemtrade leases various assets that include rail cars, private fleet, real estate, vehicles and other heavy-duty machinery and equipment. Chemtrade's ROU assets are presented below:

	Rail cars	Private Fleet	Real Estate	Vehicles	Other ⁽¹⁾	Total
Balance at January 1, 2022	\$ 104,827 \$	3,413 \$	25,916 \$	360 \$	5,919 \$	140,435
Depreciation	(38,814)	(1,190)	(2,390)	(440)	(3,571)	(46,405)
Additions	30,160	5,762	_	656	1,141	37,719
Early terminations and others (2)	(1,362)	(1,854)	(2,243)	(368)	(908)	(6,735)
Foreign exchange rate changes	1,421	301	741	3	123	2,589
Balance at December 31, 2022	96,232	6,432	22,024	211	2,704	127,603
Depreciation	(38,567)	(3,984)	(3,420)	(583)	(3,109)	(49,663)
Additions	83,891	14,341	_	1,205	7,665	107,102
Disposals (note 14)	_	_	_	_	(5,293)	(5,293)
Early terminations and others (2)	(13,435)	_	_	(133)	_	(13,568)
Foreign exchange rate changes	(667)	(281)	(196)	7	(1)	(1,138)
Balance at December 31, 2023	127,454	16,508	18,408	707	1,966	165,043

⁽¹⁾ Other includes leased assets such as heavy-duty forklifts, trucks and storage tanks.

(ii) Lease liabilities

Chemtrade's lease liabilities are composed of the following:

	2023	2022
Balance at beginning of year	\$ 139,642	\$ 148,074
Renewals and additions	107,102	37,719
Interest expense	7,771	5,893
Principal and interest repayment (1)	(64,277)	(56,546)
Disposals of assets (note 14)	(5,293)	_
Other disposals (2)	(1,030)	(3,630)
Foreign exchange rate changes	(4,028)	8,132
Total	179,887	139,642
Less: Current portion	49,304	45,571
Balance at end of year	\$ 130,583	\$ 94,071

⁽²⁾ Includes early terminations, reclassifications and other adjustments.

⁽¹⁾ Excludes sub-lease receipts of \$4,386 (2022 - \$4,257). (2) Includes early terminations, reclassifications and other adjustments.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

16. LEASES (continued):

The maturity analysis of Chemtrade's contractual undiscounted lease liabilities is presented below:

	December 31, 2023	December 31, 2022
Less than one year	\$ 57,597	\$ 50,950
One to five years	129,730	88,859
More than five years	8,846	13,298
Total undiscounted lease liabilities	\$ 196,173	\$ 153,107

(iii) Amounts recognized in profit or loss

	December 31, 2023	December 31, 2022
Depreciation	\$ 49,663	\$ 46,405
Interest expense (included in net finance costs)	7,771	5,893
Income from sub-leasing ROU assets	(557)	(76)
Expenses relating to short-term leases	4,581	3,731
Expenses relating to leases of low value assets, excluding short-term leases of low value assets	378	494

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

17. INVESTMENT IN A JOINT VENTURE:

Chemtrade owns a 49% interest in KPCT Holdings LLC ("KPCT Holdings"), a joint venture for the greenfield construction of a high purity sulphuric acid plant in Casa Grande, AZ which has been put on hold. Privately held KPPC Advanced Chemicals Inc. ("KPPC") owns the remaining 51% interest in the joint venture. During the third quarter of 2022, Chemtrade made a capital contribution of \$5,931 (US\$4,550) towards its interest in KPCT Holdings. Chemtrade's interest in KPCT Holdings is accounted for using the equity method in the consolidated financial statements. The carrying amount of the investment as of December 31, 2023 was \$4,082 (US\$3,168) (2022 - \$5,495 (US\$4,215)) which includes Chemtrade's share of loss of \$1,413 (US\$1,047) (2022 - \$436 (US\$334)) from the joint venture.

18. OTHER ASSETS:

Chemtrade's other assets are as follows:

	December 31, 2023	December 31, 2022
Interest rate swaps (note 29)	\$ -	\$ 21,067
Non-cash proceeds from sale of PPE (note 15)	5,117	5,237
Cash-settled unit swaps (note 29)	4,390	2,599
Deferred charges	_	3,141
Long-term receivables	3,675	3,241
Other	390	1,049
	\$ 13,572	\$ 36,334

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

19. INTANGIBLE ASSETS:

Chemtrade's intangible assets and goodwill are as follows:

		Goodwill	F	Customer Relationships	Other	Total
Cost				•		
Balance at January 1, 2022	\$	455,905	\$	718,399 \$	2,524 \$	1,176,828
Additions	*		*	—	212	212
Foreign exchange rate changes		21,284		17,305	92	38,681
Balance at December 31, 2022	\$	477,189	\$	735,704 \$	2,828 \$	1,215,721
Additions		_		_	33	33
Disposals (note 14)		(2,017)		_	_	(2,017)
Foreign exchange rate changes		(7,218)		(5,868)	(78)	(13,164)
Balance at December 31, 2023	\$	467,954	\$	729,836 \$	2,783 \$	1,200,573
Accumulated Amortization						
Balance at January 1, 2022	\$		\$	(570,117) \$	(2,138) \$	(572,255)
Amortization				(41,295)	(166)	(41,461)
Foreign exchange rate changes				(15,473)	(77)	(15,550)
Balance at December 31, 2022	\$	_	\$	(626,885) \$	(2,381) \$	(629,266)
Amortization		_		(38,321)	(207)	(38,528)
Foreign exchange rate changes				5,764	72	5,836
Balance at December 31, 2023	\$	_	\$	(659,442) \$	(2,516) \$	(661,958)
Net carrying amount	_		_			
December 31, 2022	\$	477,189		108,819 \$	447 \$	586,455
December 31, 2023	\$	467,954	\$	70,394 \$	267 \$	538,615

Impairment testing for cash-generating units containing goodwill

Chemtrade performed its annual test for goodwill impairment in the fourth quarter of 2023 and 2022 in accordance with its policy described in note 32. The recoverable amount of all CGUs and CGU groups exceeded their carrying values. The test was performed using a pre-tax discount rate of 13.1% to 13.4% (2022 - 12.9% to 14.3%) and a terminal growth rate of 3.0% (2022 - 3.0%). Assumptions used in the forecast operating margins and maintenance and other expenditures consider financial budgets, past experience, future growth trends such as GDP growth and inflation, associated economic risk assumptions and estimates of achieving key operating initiatives, covering a five year period.

The carrying value of goodwill for the SWC segment is \$467,954 (2022 - \$477,189) and for the EC segment is nil (2022 - nil).

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2022 and 2021

20. TRADE AND OTHER PAYABLES:

Chemtrade's payables are as follows:

	2023	2022
Trade payables	\$ 159,800	\$ 168,632
Non-trade payables and accrued expenses	139,551	147,805
	\$ 299,351	\$ 316,437

21. PROVISIONS:

			Environmental		
	Onerous Contracts	De	and commissioning liability	Legal Provision	Total
Balance at January 1, 2022	\$ _	\$	156,895	\$ 688	\$ 157,583
Adjustments ⁽¹⁾	_		(6,124)	_	(6,124)
Additions	3,941		1,536	922	6,399
Accretion	_		2,892	_	2,892
Payments	_		(8,414)	_	(8,414)
Foreign exchange rate changes	_		6,003	109	6,112
	3,941		152,788	1,719	158,448
Less: Current portion	3,941		17,162	1,719	22,822
Balance at December 31, 2022	\$ _	\$	135,626	\$ _	\$ 135,626
Balance at January 1, 2023	3,941		152,788	1,719	158,448
Adjustments included in PPE ⁽¹⁾	_		(8,532)	_	(8,532)
Adjustments included in net earnings	(3,941))	7,232	(396)	2,895
Additions	_		_	31,301	31,301
Accretion	_		2,483	_	2,483
Payments	_		(9,995)	(1,033)	(11,028)
Foreign exchange rate changes	_		(1,530)	(71)	(1,601)
	_		142,446	31,520	173,966
Less: Current portion	_		23,765	31,520	55,285
Balance at December 31, 2023	\$ _	\$	118,681	\$ _	\$ 118,681

⁽¹⁾ Includes adjustments due to change in discount rates in 2023 and 2022.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

21. PROVISIONS (continued):

(a) Environmental and Decommissioning liability

Chemtrade has estimated a provision for its environmental liability in association with its sites. Expenditures are expected to occur on dates ranging from 2024 to 2051. Chemtrade has estimated a decommissioning liability for its plants and has accrued for this obligation. Decommissioning is expected to occur on dates ranging from 2024 to 2050.

(b) Legal provision

Chemtrade has estimated an overall provision for litigation. Provisions are calculated based on a current estimate of the amounts that will be incurred in settling outstanding legal matters.

In December 2022, Chemtrade received a judgment in its favour related to a \$25,000 lawsuit against Superior Plus Corporation ("Superior"). The lawsuit involved the failed attempt by Superior to acquire Canexus Corporation ("Canexus"), prior to Chemtrade's 2017 acquisition of Canexus. During 2023, Chemtrade received a payment of \$28,119 including interest. However, Superior has filed an appeal against the judgment. Chemtrade has established a provision of \$28,119 due to uncertainty associated with the outcome of the appeal.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

22. LONG-TERM DEBT:

Changes in long-term debt are as follows:

	Revolving credit (US\$ denominated) ⁽¹⁾	((Revolving credit Cdn\$ denominated) ⁽¹⁾	Total
Maturity	December 24, 2026		December 24, 2026	
Balance at January 1, 2022	\$ 370,026	\$	3,505 \$	373,531
Net change	(31,088)		(3,505)	(34,593)
Loss on net investment hedge of foreign operations	31,255		_	31,255
Foreign exchange rate changes	(169)		_	(169)
Balance at December 31, 2022	\$ 370,024	\$	- \$	370,024
Net change	(121,547)		398	(121,149)
Gain on net investment hedge of foreign operations	(2,585)		_	(2,585)
Foreign exchange rate changes	255		_	255
Balance at December 31, 2023	\$ 246,147	\$	398 \$	246,545

⁽¹⁾ At December 31, 2023 and 2022, Chemtrade had committed a total of \$18,594 and \$19,796, respectively, of the revolving credit facilities ("Credit Facilities") towards standby letters of credit. At December 31, 2023 and 2022, Cdn\$ limit of the Credit Facilities was \$860,795 (US\$650,000) and \$881,010 (US\$650,000), respectively, and Chemtrade had drawn US\$185,870 and Cdn\$398 and US\$273,000 and Cdn\$nil, respectively, on the Credit Facilities.

In June 2022, Chemtrade amended certain terms of its Credit Facilities to allow for the investment in KPCT Holdings, a joint venture with a joint venture partner, KPPC and to recognize any cash distributions received from this joint venture in the calculation of EBITDA for debt covenant purposes.

Prior to September 2022, Chemtrade's Credit Facilities bore variable rates of interest based on the US LIBOR and Canadian Bankers' Acceptance rates. In September 2022, Chemtrade amended certain terms of its Credit Facilities and interest rate swap arrangements to replace US LIBOR with Secured Overnight Financing Rate ("SOFR").

The Credit Facilities are secured by substantially all of Chemtrade's assets in North America. At December 31, 2023, the weighted average effective interest rate of the facilities was 3.5% (December 31, 2022 - 3.1%). Interest rates on the Credit Facilities are based on SOFR and Canadian Bankers' Acceptance rates, adjusted by Chemtrade's credit spread.

Chemtrade is subject to certain covenants pursuant to its Credit Facilities, which include a Net debt to EBITDA ratio and an Interest Coverage ratio (as such terms are defined in the credit agreement). Chemtrade monitors these ratios and reports them to its lenders on a quarterly basis. As at December 31, 2023 and December 31, 2022, Chemtrade was in compliance with all covenants.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

23. CONVERTIBLE UNSECURED SUBORDINATED DEBENTURES:

Changes in convertible unsecured subordinated debentures are as follows:

Changes in conventible uni	secured subo	rumateu deb	entures are	as ioliows.						
Convertible unsecured subordinated debentures (1)										
	Fund 2016 5.00% Debentures	Fund 2017 4.75% Debentures	Fund 2019 6.50% Debentures	Fund 2020 8.50% Debentures	Fund 2021 6.25% Debentures	Fund 2023 7.00% Debentures	Total			
Maturity	August 31, 2023		October 31, 2026		August 31, 2027	June 30, 2028				
Interest rate	5.00 %	4.75 %	6.50 %	8.50 %	6.25 %	7.00 %				
Principal outstanding at January 1, 2022	143,750	201,115	100,000	86,250	130,000	_	661,115			
Principal outstanding at December 31, 2022	_	201,115	100,000	86,250	130,000	_	517,365			
Principal outstanding at December 31, 2023	_	_	100,000	85,552	130,000	110,000	425,552			
Balance at January 1, 2022	143,894	197,796	101,150	97,463	129,870	_	670,173			
Redemption (2)	(143,750)	_	_	_	_	_	(143,750)			
Change in fair value recognized in profit or loss	(144)	(12,502)	(8,858)	15,131	13,996	_	7,623			
Change in fair value due to own credit risk ⁽⁵⁾	_	9,989	5,218	(4,782)	(11,253)	_	(828)			
Balance at December 31, 2022	_	195,283	97,510	107,812	132,613	_	533,218			
Issuance (3)	_	_	_	_	_	110,000	110,000			
Redemption (4)	_	(201,115)	_	_	_	_	(201,115)			
Conversion	_	_	_	(698)	_	_	(698)			
Change in fair value recognized in profit or loss	_	4,992	(1,928)	(22,988)	(8,231)	(5,683)	(33,838)			
Change in fair value due to own credit risk ⁽⁵⁾	_	840	2,668	17,681	6,268	2,493	29,950			
Balance at December 31,			00.050	404.007	400.050	100.010	40= =4=			

⁽¹⁾ The Fund 2017 4.75% Debentures, the Fund 2019 6.50% Debentures, the Fund 2020 8.50% Debentures, the Fund 2021 6.25% Debentures, the Fund 2023 7.00% Debentures and the Fund 2016 5.00% Debentures (which latter Debentures were redeemed during the first quarter of 2022) are collectively referred to as the "Debentures". Chemtrade has designated the Debentures as financial liabilities at fair value through profit or loss.

98.250

101,807

130.650

106.810

437.517

2023

During the first quarter of 2022, Chemtrade redeemed all of the outstanding Fund 2016 5.00% Debentures for their par value, including accrued interest for a total of \$146,645. Chemtrade used the net proceeds from the Fund 2021 6.25% Debentures offering and its Credit Facilities to fund the redemption.

⁽³⁾ During the first quarter of 2023, Chemtrade completed a public offering of the Fund 2023 7.00% Debentures, at a price of \$1,000 per debenture. The Fund 2023 7.00% Debentures are convertible, at the option of the holder, into trust units of the Fund at a conversion price of \$12.85 per unit. Chemtrade incurred transaction costs of \$4,980 which included underwriters' fees and other expenses relating to the offering.

⁽⁴⁾ During the second quarter of 2023, Chemtrade redeemed all of the outstanding Fund 2017 4.75% Debentures for their par value, including accrued interest for a total of \$203,527. Chemtrade used the net proceeds from the Fund 2023 7.00% Debentures offering, a portion of its Credit Facilities and cash on hand to fund the redemption.

⁽⁵⁾ The change in fair value of the Debentures due to Chemtrade's own credit risk has been presented in other comprehensive income, net of taxes, rather than net earnings.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

23. CONVERTIBLE UNSECURED SUBORDINATED DEBENTURES (continued):

For the year ended December 31, 2023, interest expense of \$32,200 (2022 - \$32,004) and transaction costs of \$4,980 (2022 - \$nil) relating to the Debentures were recognized in net finance costs.

24. OTHER LONG-TERM LIABILITIES:

Chemtrade's other long-term liabilities are as follows:

		2023	2022
Long Assess a series of LTIP link little (seeks 0.7)	4	40 404	40.040
Long-term portion of LTIP liability (note 27)	\$	18,434	\$ 16,646
Other		4,794	4,925
	\$	23,228	\$ 21,571

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

25. EMPLOYEE BENEFITS:

Chemtrade provides certain health care and pension benefits for certain employees upon retirement.

Generally, under the pension plans, Chemtrade provides retirement benefits based on an employee's years of service and average annual earnings over a period of time prior to retirement. Chemtrade is responsible for meeting its statutory obligations for funding of the pension plans.

Certain hourly employees participate in the Pulp and Paper Industry Pension Trust Fund, a multi-employer, negotiated costs defined benefit plan. The plan is funded by employer and employee contributions. The employer-related expense under this plan in 2023 was \$299 (2022 - \$265).

All eligible Canadian employees participate in a defined contribution pension ("DC") plan. The DC plan is self-directed. Participants choose from a range of investment options offered by the plan administrator. Chemtrade provides a basic contribution of 4% of base salary for participants. Participants can make additional voluntary contributions up to 2% of their base salary, and Chemtrade matches each dollar contributed up to 2% for a total of 6% of base salary. Chemtrade's contributions to the DC plan vest immediately. The employer-related expense under this plan in 2023 was \$3,045 (2022 - \$2,936).

Chemtrade also provides other employee future benefits, including health and dental care benefits and life insurance, for retired employees.

Short-term employee benefits for current employees, such as salaries, paid absences, bonuses and other benefits, are accounted for on an accrual basis over the period in which the employees provide the related services. In 2023, \$195,230 (2022 - \$179,880) of short-term employee benefits were recognized in cost of sales and services, and \$74,523 (2022 - \$62,383) were recognized in selling and administrative expenses.

Chemtrade expects \$1,922 in contributions to be paid to its defined benefit plans in 2024.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

Gain recognized in OCI during the year

25. EMPLOYEE BENEFITS (continued):

		2023		0000
		2023		2022
Present value of unfunded obligations	\$	6,701	¢	6,856
Present value of funded obligations	Ψ	261,265	Ψ	271,176
Total present value of obligations		267,966		278,032
Fair value of plan assets		(248,649)		(252,036)
Recognized liability for defined benefit obligations prior to asset		(240,049)		(232,030)
ceiling		19,317		25,996
Effect of asset ceiling		1,174		1,559
Recognized liability for defined benefit obligations	\$	20,491	\$	27,555
		2023		2022
Components of net periodic benefit cost				
Current service cost	\$	1,276	\$	2,278
Past service cost		(117)		_
Net interest cost		1,515		701
Administration costs		1,905		1,780
Plan settlements		172		171
Net periodic benefit cost recognized	\$	4,751	\$	4,930
		2023		2022
Net periodic benefit cost allocation				
Cost of sales and services	\$	1,191	\$	2,170
Selling and administrative expenses		2,045		2,059
Net finance costs		1,515		701
Net periodic benefit cost recognized	\$	4,751	\$	4,930
		2023		2022
Other comprehensive income		2020		2022
Return on plan assets, excluding interest income	\$	(14,351)	\$	65,377
Actuarial loss (gain)	Ψ	5,290	Ψ	(68,625)
Effect of asset ceiling		(464)		1,559
Liteot of about belling		(+04)	_	1,000

\$

(9,525) \$

(1,689)

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

25. EMPLOYEE BENEFITS (continued):

	2023	2022
Weighted average assumptions		
Discount rate	4.80 %	5.09 %
Ultimate other medical trend rate	4.50 %	4.50 %
Salary escalation	3.00 %	3.00 %
	2023	2022
Change in accrued benefit obligation		
Accrued benefit obligation at beginning of year	\$ 278,032 \$	381,108
Current service cost	1,276	2,278
Interest cost	13,571	9,380
Employee contributions	212	249
Benefits paid	(19,063)	(26,609)
Plan settlements	(7,866)	(33,517)
Foreign exchange rate changes	(3,369)	13,768
Past service cost	(117)	_
Actuarial loss from changes in demographic assumptions	175	3,328
Actuarial loss (gain) from changes in financial assumptions	7,280	(78,996)
Actuarial (gain) loss from experience adjustments	(2,165)	7,043
Accrued benefit obligation at end of year	\$ 267,966 \$	278,032
	2023	2022
Change in plan assets		
Plan assets at beginning of year	\$ 252,036 \$	355,848
Administration fee	(1,905)	(1,839)
Interest income	12,135	8,679
Employer contributions	1,857	2,366
Employee contributions	212	249
Benefits paid	(19,063)	(26,609)
Foreign exchange rate changes	(2,936)	12,407
Plan settlements	(8,038)	(33,688)
Return on plan assets, excluding interest income	14,351	(65,377)
Plan assets at end of year	\$ 248,649 \$	252,036
	2023	2022
Change in asset ceiling		
Asset ceiling at beginning of year	\$ 1,559 \$	_
Change in asset ceiling	(464)	1,559
Interest on asset ceiling	79	_
Asset ceiling at end of year	\$ 1,174 \$	1,559

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

25. EMPLOYEE BENEFITS (continued):

In 2023 and 2022, Chemtrade completed annuity purchases with respect to former employees. These activities are designed to reduce Chemtrade's defined benefit plan obligations and decrease future risks and volatility associated with these obligations. Chemtrade paid \$8,038 (2022 - \$33,688) from the impacted plans' assets to settle \$7,866 (2022 - \$33,517) of pension obligations and recorded \$172 (2022 - \$171) settlement charge in selling and administrative expenses. The settlement charges resulted from the difference between the amount paid for the annuity purchases and the value of Chemtrade's defined benefit plan obligations related to these annuity purchases at the time of the settlement.

The asset mix in the plan is approximately 68.1% bonds (2022 - 64.9%), approximately 23.0% equity securities (2022 - 24.4%) and approximately 8.9% other investments (2022 - 10.7%).

Assumed discount rates, inflation rates and mortality rates have an effect on the amounts recognized on the consolidated statements of financial position. Holding other assumptions constant, changes in key assumptions that are reasonably possible would have affected the defined benefit obligation by the amounts shown below:

	Defined benefit obligation			
	Increase	Decrease		
Discount rate (1% movement)	\$ (23,854) \$	28,399		
Inflation rate (1% movement)	\$ 8,416 \$	(2,623)		
Mortality rate (10% movement)	\$ (6,729) \$	7,298		

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

26. UNITS AND OTHER COMPONENTS OF EQUITY:

(a) Units:

Chemtrade has authorized an unlimited number of units. Chemtrade's units have no par value. The following table presents the number of units outstanding:

	2023		2022	
	Number of Units	Amount	Number of Units	Amount
Balance - January 1	115,536,668 \$	1,635,683	104,222,562 \$	1,541,583
Issuance of units for cash	_	_	10,005,000	86,543
Issuance costs, net of tax recovery of \$nil (2022 - \$1,214)	_	_	_	(2,877)
Conversion of unsecured subordinated convertible debentures	94,964	698	_	_
Issuance of units under the DRIP	1,416,672	12,030	1,309,106	10,434
Balance – December 31	117,048,304 \$	1,648,411	115,536,668 \$	1,635,683

On August 22, 2022, Chemtrade completed an equity offering of 10,005,000 units at a price of \$8.65 per unit, resulting in total gross proceeds of \$86,543. Chemtrade incurred issuance costs of \$2,877, net of tax recovery of \$1,214, which included underwriters' fees and other expenses relating to the offering. Proceeds from the offering were used to repay outstanding indebtedness under the Credit Facilities.

(b) Contributed surplus:

Chemtrade's contributed surplus relates to the re-purchase of units under a normal course issuer bid.

(c) Accumulated other comprehensive income ("AOCI"):

AOCI is comprised of the following separate components of equity:

Cumulative translation account

The cumulative translation account comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

Unrealized gains/losses on cash flow and net investment hedges

The hedging reserve comprises the effective portion of the cumulative net change in the fair value of cash flow hedging instruments related to hedged transactions that have not yet occurred. The reserve also comprises the cumulative foreign currency differences arising on the translation of Chemtrade's U.S. dollar-denominated long-term debt, which is designated as the hedge of the net investment in foreign operations that use the U.S. dollar.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

26. UNITS AND OTHER COMPONENTS OF EQUITY (continued):

Change in fair value of convertible debentures due to credit risk

The Debentures are recognized initially at fair value. Subsequent to initial recognition, the Debentures are measured at fair value at each period end date with the changes recorded in comprehensive income. Any changes in the fair value due to Chemtrade's own credit risk are presented in other comprehensive income rather than net earnings.

(d) Distributions:

Distributions paid for the year ended December 31, 2023 were \$70,061 (2022 - \$65,187) or \$0.60 per unit (2022 - \$0.60 per unit). Of the distributions paid for the year ended December 31, 2023, \$58,031 (2022 - \$54,753) were in cash and \$12,030, (2022 - \$10,434) were reinvested in additional units pursuant to the DRIP. All of Chemtrade's distributions are discretionary and subject to Board approval.

Distributions declared, including the DRIP bonus distributions for the year ended December 31, 2023 were \$70,140 (2022 - \$65,760) or \$0.60 per unit (2022 - \$0.60 per unit).

As at December 31, 2023, Chemtrade had distributions payable of \$5,884 (December 31, 2022 - \$5,805). On January 26, 2024, distributions of \$4,814 were paid in cash and \$1,070 were reinvested in additional units pursuant to the DRIP. On January 22, 2024, Chemtrade declared a cash distribution of \$0.055 per unit for the month of January 2024 payable on February 26, 2024 to Unitholders of record at the close of business on January 31, 2024. Chemtrade is suspending its DRIP effective with the distribution declared in January 2024 and payable in February 2024, at which time all distributions of the Fund will be paid only in cash.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

27. SHARE-BASED PAYMENTS:

Chemtrade operates a Long-term Incentive Plan ("LTIP"), which grants cash awards based on certain criteria. The 2021 - 2023 LTIP awards have a performance based component and a Restricted Share Unit ("RSU") component. The 2022 - 2024 and 2023 - 2025 LTIP awards have a performance based Performance Share Unit ("PSU") component and a RSU component. The performance based component of the 2021 - 2023 LTIP awards and performance based PSU component of the 2022 - 2024 and 2023 - 2025 LTIP are based on return on investment capital improvement and total return to Chemtrade's Unitholders relative to the total return of companies comprising the S&P/TSX Dividend Composite Index. Total Unitholder return consists of changes in unit price and distributions paid to Unitholders over the course of the performance periods. The performance based PSU component under 2022 - 2024 and 2023 - 2025 LTIP awards is also adjusted by Environmental, Social and Governance goals to be achieved by the end of the performance period. The RSU component of the LTIP awards is a phantom plan which is payable in cash at the end of the performance period.

As at December 31, 2023, a liability of \$33,640 (December 31, 2022 - \$52,327) has been recorded, of which \$15,206 (December 31, 2022 - \$35,681) is included in trade and other payables and \$18,434 (December 31, 2022 - \$16,646) is included in other long-term liabilities. During the first quarter of 2023, Chemtrade paid \$36,311 to settle the 2020 - 2022 LTIP awards. For the year ended December 31, 2023, Chemtrade recorded an expense of \$17,332 (2022 - \$20,971) in selling and administrative expenses related to the fair value adjustments on the LTIP.

The following RSUs under these plans are outstanding:

Number of rights

	2023	2022
Balance – January 1	3,293,965	3,596,918
Grants – new grants	647,758	813,870
 distribution equivalents 	172,131	254,733
Forfeitures	(78,813)	(49,375)
Settlements	(1,819,736)	(1,322,181)
Balance – December 31	2,215,305	3,293,965

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

27. SHARE-BASED PAYMENTS (continued):

The following PSUs under these plans are outstanding:

	Number	of rights
	2023	2022
Balance – January 1	1,398,638	_
Grants – new grants	637,656	728,040
 estimated performance adjustment 	423,659	604,206
 distribution equivalents 	156,473	102,174
Forfeitures	(73,825)	(29,437)
Settlements	(7,034)	(6,345)
Balance – December 31	2,535,567	1,398,638

Chemtrade has in place a deferred unit plan ("DUP") for non-employee trustees ("Participants"), pursuant to which the Participants can elect to take all or a portion of their compensation in the form of deferred units of Chemtrade, with the remainder as a cash payment. The deferred units are settled in units of the Fund issued from treasury or in cash at the Participant's request. Currently, the Participants are required to take a minimum of 50% of their compensation in the form of deferred units of Chemtrade. As at December 31, 2023, 677,402 deferred units at a value of \$5,771 were outstanding (December 31, 2022 - 583,501 deferred units at a value of \$5,234).

The following rights under the DUP are outstanding:

	Number of rig	Ints
	2023	2022
Balance – January 1	583,501	569,017
Grants – new grants	121,642	99,461
 distribution equivalents 	41,680	45,023
Settlements	(69,421)	(130,000)
Balance – December 31	677,402	583,501

Number of simble

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

27. SHARE-BASED PAYMENTS (continued):

Inputs for measurement of fair values

The inputs used in the measurement of the fair value of the share-based component of LTIP are as follows:

	December 31, 2023	December 31, 2022
Chemtrade units:		
Average base price Period-end unit price Average expected volatility	\$7.84 \$8.52 31.00%	\$6.35 \$8.97 32.47%
Average risk free interest rate Average expected remaining term	4.14% 1.50 years	4.20% 1.50 years

28. COMMITMENTS AND CONTINGENCIES:

(a) Purchase commitments

Chemtrade has contractual commitments for the purchase of electricity in Brazil, of which approximately 90 to 100 percent of the cost is passed onto one major customer, and minimum purchase commitments under certain multi-year salt supply contracts and contractual commitments for PPE. Chemtrade's outstanding purchase commitments as at December 31, 2023 are as follows:

2024	58,891
2025	41,130
2026	26,289
	\$ 126,310

(b) Decommissioning and Environmental costs

Chemtrade's operations are subject to numerous laws, regulations and guidelines relating to air emissions, water discharges, solid and hazardous wastes, transportation and handling of hazardous substances and employee health and safety in Canada, the United States and other countries where they operate. These environmental regulations are continually changing and are generally becoming more restrictive.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

28. COMMITMENTS AND CONTINGENCIES (continued):

(c) Contingent assets

In December 2022, Chemtrade received a judgment in its favour related to a \$25,000 lawsuit against Superior. The lawsuit involved the failed attempt by Superior to acquire Canexus, prior to Chemtrade's 2017 acquisition of Canexus. During 2023, Chemtrade received a payment of \$28,119 including interest. However, Superior has filed an appeal against the judgment. Chemtrade has established a provision of \$28,119 due to uncertainty associated with the outcome of the appeal.

29. FINANCIAL INSTRUMENTS:

(a) Categories of financial assets and liabilities

The carrying values of Chemtrade's financial instruments are as follows:

	IFRS 9 Classification	2023	2022
Cash-settled unit swaps Cash-settled unit swaps Interest rate swap asset (notes 13.18)	Fair value - hedging instrument Fair value through profit and loss Fair value through profit and loss	\$ 6,252 1,332 10,886	\$ 6,982 — 21,067
Foreign exchange contracts asset (liability)	Fair value through profit and loss	2,483	(3,752)
Convertible unsecured subordinated debentures (note 23) (1)	Fair value through profit and loss	437,517	533,218
Trade and other receivables (note 11)	Amortized cost	146,686	123,214
Trade and other payables (note 20)	Other financial liabilities	299,351	316,437
Distributions payable (note 26)	Other financial liabilities	5,884	5,805
Long-term debt (note 22)	Other financial liabilities	246,545	370,024

⁽¹⁾ Any changes in the fair value due to Chemtrade's own credit risk are presented in other comprehensive income rather than net earnings.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

(b) Derivatives and hedging:

		Decembe	er 31, 2023		December	r 31, 2022
	Notional	Fair	Value	Notional	Fair \	/alue
	Amount	Asset	Liability	Amount	Asset	Liability
Derivatives designated in a formal hedging relationship						
Cash-settled unit swaps (1)	_	\$ 6,252	\$ —	_	\$ 6,982	\$ —
Derivatives not designated in a formal hedging relationship						
Interest rate swaps (1)	US\$ 325,000	10,886	_	US\$ 325,000	21,067	_
Foreign exchange contracts (1)(2)	_	2,483	_	_	_	3,752
Cash-settled unit swaps (1)	_	1,332	_	_	_	_
Total		\$ 20,953	\$ —		\$ 28,049	\$ 3,752

⁽¹⁾ Current portion of assets is included in Prepaid expenses and other assets, non-current portion of assets is included in Other assets, current portion of liabilities is included in Trade and other payables and non-current portion of liabilities is included in Other long-term liabilities in the Consolidated Statements of Financial Position as of December 31, 2023 and December 31, 2022

As of January 1, 2022, Chemtrade had swap arrangements in place to fix the LIBOR components of its interest rates on US\$325,000 of its Credit Facilities until October 2024. During the first quarter of 2022, Chemtrade formally designated the interest rate swaps as cashflow hedges. Subsequent to the designation, changes in the fair value of the effective portion of the swaps were recognized in other comprehensive income.

During the third quarter of 2022, Chemtrade de-designated its interest rate swaps and hedge accounting on these swaps was discontinued prospectively. For the year ended December 31, 2023, Chemtrade reclassified \$7,017, (2022 - \$5,953) relating to the changes in fair value of the effective portion of the swaps from other comprehensive income to net earnings, as a result of the de-designation. For the year ended December 31, 2023, Chemtrade recognized a loss of \$10,181, (2022 - a gain of \$10,692) relating to the changes in the fair value of the dedesignated swaps, in net earnings.

In September 2022, Chemtrade amended certain terms of its Credit Facilities and interest rate swap arrangements to replace US LIBOR with SOFR.

Chemtrade hedges its investment in foreign operations that use the U.S. dollar as their functional currency by Chemtrade's U.S. dollar-denominated bank debt. Any foreign currency gains and losses arising from the U.S. dollar-denominated debt will be offset by the foreign currency gain or loss arising from the investment in the foreign operations. The gains and losses on the foreign currency translation of the designated amount of U.S. dollar-denominated debt and investment in foreign operations are recognized in other comprehensive income.

⁽²⁾ See below for notional amounts.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

For the year ended December 31, 2023, a foreign exchange gain of \$2,585 (2022 - loss of \$31,255) on the revaluation of the U.S. dollar-denominated debt related to this hedging strategy was recognized in other comprehensive income, net of tax.

During 2021, Chemtrade entered into cash-settled unit swap arrangements which fixed the unit price on a portion of the RSU component of its LTIP awards. During the first quarter of 2022, Chemtrade rolled over the hedged units maturing on March 31, 2022, into 2023, 2024 and 2025. In addition to a portion of the RSU component of its LTIP awards, these arrangements fixed the unit price of a portion of the PSU component of its 2022 - 2024 LTIP awards. During the first quarter of 2023, Chemtrade rolled over the hedged units maturing on March 31, 2023, into 2024, 2025 and 2026. In addition to a portion of the RSU component of its LTIP awards, these arrangements fixed the unit price of the PSU component of its 2023 - 2025 LTIP awards and deferred units awarded under the DUP. The RSU component of the LTIP awards is a phantom plan which is payable in cash at the end of the performance period. The PSU component of the LTIP awards gives a right to the participants to receive cash payments upon the achievement of performance goals during the performance periods. The arrangements are based on a portion of RSUs and PSUs outstanding for all its existing LTIP awards. As at December 31, 2023, the notional number of units hedged was 2,439,105 with maturity dates ranging between March 2024 and March 2026. Distributions on the hedged units are reinvested in these swap arrangements. The RSU and PSU swaps are formally designated as cash flow hedges at the date of inception and any changes in the fair value of the unvested portion of the RSUs and PSUs are recognized in other comprehensive income. However, the swaps which fix the unit price on deferred units are not formally designated as cash flow hedges and any changes in the fair value of these deferred units swaps are recognized in net earnings. As at December 31, 2023, the notional number of units not hedged was 548,568 maturing in March 2024.

Chemtrade has entered into foreign exchange contracts to manage some of its exposure to foreign currencies. Chemtrade buys and sells specific amounts of currencies at pre-determined dates and exchange rates, which are matched with the anticipated operational cash flows. Contracts in place at December 31, 2023 include future contracts to sell the following amounts for periods through to April 2025:

Amount	Maturity	Exchange rate
US\$63,736	Q1 2024	\$1.34
US\$22,147	Q2 2024	\$1.34
US\$17,247	Q3 2024	\$1.34
US\$10,131	Q4 2024	\$1.34
US\$7,000	Q1 2025	\$1.36
US\$3,000	Q2 2025	\$1.37

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

(c) Fair values of financial instruments:

Fair value is the value that would be agreed upon in an arm's length transaction between willing and knowledgeable counter-parties. The carrying amounts of cash and cash equivalents, trade and other receivables, trade and other payables and distributions payable approximate their fair values because of the short-term maturity of these financial instruments. The carrying amount of long-term debt, approximates fair value as the debt accrues interest at variable interest rates.

For fair value estimates relating to the Debentures and derivatives, Chemtrade classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - Unadjusted quoted prices at the measurement date for identical assets or liabilities in active markets.

Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 - Significant unobservable inputs which are supported by little or no market activity.

The following is a summary of the fair value hierarchy levels of Chemtrade's financial instruments:

2023	Level 1	Level 2	Level 3	Total
Instruments designated as fair value through profit and loss				
Interest rate swaps	\$ — \$	10,886 \$	— \$	10,886
Foreign exchange contracts	_	2,483	_	2,483
Cash-settled unit swaps	_	1,332	_	1,332
Convertible unsecured subordinated debentures	(437,517)	_	_	(437,517)
Instruments designated as fair value through other comprehensive income				
Cash-settled unit swaps	_	6,252	_	6,252
Total	\$ (437,517) \$	20,953 \$	— \$	(416,564)

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

2022	Level 1	Level 2	Level 3	Total
Instruments designated as fair value through profit and loss				
Interest rate swaps	\$ — \$	21,067 \$	— \$	21,067
Foreign exchange contracts	_	(3,752)	_	(3,752)
Convertible unsecured subordinated debentures	(533,218)	_	_	(533,218)
Instruments designated as fair value through other comprehensive income				
Cash-settled unit swaps	_	6,982	_	6,982
Total	\$ (533,218) \$	24,297 \$	— \$	(508,921)

The Fund's Debentures are classified within Level 1 because they are actively traded on the TSX and the fair value is based on the quoted prices on the TSX. Any changes in the fair value of the Debentures are recognized in net earnings except for changes due to the Fund's own credit risk which are recorded in other comprehensive income.

All of Chemtrade's derivative financial instruments are classified within Level 2 because they are based on rates quoted by banks and other public data sources. These derivatives are recorded in prepaid expenses and other assets, trade and other payables, and other long-term liabilities on the statements of financial position.

The fair value of the foreign exchange contracts is the difference between the forward exchange rate and the contract rate. Any changes in the fair value of these contracts are recognized in net earnings.

The fair value of the interest rate swap arrangements is the difference between the forward interest rates and the contract rates discounted. The assets or liabilities are recorded in prepaid expenses and other assets, other assets or other long-term liabilities in the statements of financial position. Prior to de-designation, any changes in the effective portion of fair value of these arrangements were recognized in other comprehensive income. Any changes in the fair value of these arrangements de-designated for hedge accounting are recognized in net earnings.

The fair value of the cash-settled unit swap arrangements is the difference between the forward unit price and the contract unit price. These swaps are recorded in prepaid expenses and other assets, and other long-term liabilities on the statements of financial position. Any changes in the fair value of the unvested portion of the RSUs and PSUs are recognized in other comprehensive income. Any changes in the fair value of the deferred units under the DUP are recognized in net earnings.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

(d) Risks associated with financial instruments

(i) Credit risk

Credit risk arises from the non-performance by counter-parties of their contractual financial obligations. Chemtrade manages credit risk for trade and other receivables through established credit monitoring activities. Chemtrade does not have a significant concentration of credit risk with any single counter-party. The primary counter-parties related to the foreign exchange forward contracts and interest rate swaps carry investment grade ratings. Chemtrade believes its credit risk of counterparty non-performance continues to be relatively low. Chemtrade is in regular contact with its customers, suppliers and logistics providers, and to date has not experienced significant counter-party non-performance. However, if a key supplier or customer experiences financial difficulties or fails to comply with their contractual obligations, this could result in a significant financial loss to Chemtrade. Chemtrade's maximum exposure to credit risk at the reporting date is the carrying value of its receivables and derivative assets.

(ii) Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. Chemtrade manages liquidity risk by maintaining adequate cash and cash equivalent balances, and by appropriately utilizing its lines of credit. Chemtrade believes that cash flows from operating activities, together with cash on hand, cash from receivables and borrowings available under the revolving credit facility are sufficient to fund its currently anticipated financial obligations, and will remain available in the current environment.

The undiscounted cash flow requirements for financial liabilities as at December 31, 2023 are as follows:

	Carrying Value	Total	L	ess Than 1 Year	2-3 Years	4-5 Years	After 5 Years
Trade and other payables (note 20)	\$ 299,351	\$ 299,351	\$	299,351	\$ _	\$ —	\$ _
Distributions payable (note 26)	5,884	5,884		5,884	_	_	_
Lease liabilities (note 16)	179,887	196,173		57,597	83,062	46,668	8,846
Long-term debt (note 22)	246,545	246,545		_	246,545	_	_
Interest on long-term debt	_	43,172		10,625	32,547	_	_
Convertible unsecured subordinated debentures (note 23)	437,517	425,552		_	185,552	240,000	_
Interest on Debentures	_	95,589		29,597	49,021	16,971	_
Total	\$ 1,169,184	\$ 1,312,266	\$	403,054	\$ 596,727	\$ 303,639	\$ 8,846

Notes to Consolidated Financial Statements
(In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

(iii) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and price risk (unit and other). Chemtrade's market risks are as follows:

(a) Currency risk

Chemtrade is exposed to fluctuations in the exchange rate of the U.S. dollar relative to the Canadian dollar as a portion of Chemtrade's earnings are in U.S. dollars, with earnings positively affected when the U.S. dollar strengthens relative to the Canadian dollar. At December 31, 2023, on an unhedged basis, Chemtrade estimates that a one-cent change in the exchange rate would have an impact on the translation of net earnings of approximately \$3,000 per annum. At December 31, 2023, on an unhedged basis, a one-cent change in the exchange rate would also have an impact of approximately \$1,900 on Chemtrade's net earnings because of the translation of its U.S. dollar-denominated long-term debt. Chemtrade cannot predict changes in currency exchange rates, the impact of exchange rate changes on Chemtrade's operating results, nor the degree to which Chemtrade will be able to manage the impact of currency exchange rate changes. Such changes could have an impact on Chemtrade's business, results of operations and financial condition.

(b) Interest rate risk

Chemtrade has a credit facility with long-term debt which bears variable rates of interest. As at December 31, 2023, on an unhedged basis, a change in interest rates of 1% per annum would have an impact of approximately \$2,500 on Chemtrade's net earnings per annum. As at December 31, 2023, Chemtrade had fixed interest rates on 100% of its Credit Facilities until October 2024 through interest rate swaps and 0% thereafter until December 2026.

(c) Unit price risk

Unit price risk is the risk that changes in Chemtrade's own unit price affect earnings and cash flows. Earnings and cash flows from operating activities are affected when outstanding cash-settled RSUs and PSUs, issued under Chemtrade's LTIP awards and deferred units under DUP are revalued each period based on Chemtrade's unit price. Net cash flows from operating activities are affected when these cash-settled RSUs, PSUs and DUP units are ultimately settled. Chemtrade enters into cash-settled unit swap arrangements to fix the unit price on a portion of the RSU and PSU components of its LTIP awards and deferred units under DUP to mitigate a portion of the unit price risk.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

(d) Other price risks

Product Price and Sales Volume Risk -

Every \$50 change in the price per metric tonne ("MT") of North American produced sodium chlorate would have an impact on earnings before income taxes of approximately \$14,150 per annum. Every \$100 change in the price per MECU of chlor-alkali products produced in North America would have an impact on earnings before income taxes of approximately \$18,100 per annum. These sensitivities to changes in prices are based on approximately 283,000 MT of North American sodium chlorate sales and 181,000 MECU of North American chlor-alkali sales for the year ended December 31, 2023, respectively.

A change in sales volumes for North American sodium chlorate of 10,000 MT would have an impact on earnings before income taxes of approximately \$4,990 per annum. A change in sales volumes for North American chlor-alkali products of 5,000 MECU would have an impact on earnings before income taxes of approximately \$7,500 per annum.

Electricity Price Risk -

Every four percent change in the price of electricity in North America would have an impact on earnings before income taxes of approximately \$3,700 per annum. This sensitivity to changes in electricity prices is based on North American electricity consumption of approximately 1,907,000 megawatt hours for the year ended December 31, 2023. A four percent change in the price of electricity in North America is considered reasonable given historical price changes and market expectations for future movement.

Sulphuric acid pricing -

At December 31, 2023, a change in sulphuric acid pricing, net of freight, of \$10 per tonne, would have an impact on annual revenues in North America of approximately \$9,300. In any specific period, the exact impact would depend upon the volume that is subject to sales contracts where pricing has been fixed for a period of time. The magnitude of realized price changes also depends upon regional market dynamics. It is difficult to reliably estimate the impact of price changes on earnings as this depends upon the volume subject to risk-sharing supply contracts and changes in sulphur costs for manufactured sulphuric acid. These factors lessen the impact of price changes on earnings relative to revenue.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

29. FINANCIAL INSTRUMENTS (continued):

Salt costs -

Chemtrade uses salt in the manufacturing of its sodium chlorate and chlor-alkali products. At current operating levels, an increase of \$2 per tonne of salt prices in North America would have an impact of approximately \$1,000 per annum on earnings before income taxes.

Sulphur costs -

Chemtrade uses sulphur in the manufacturing of several of its products, including sulphuric acid. At operating levels as at December 31, 2023, an increase of \$10 per tonne would have an impact of approximately \$1,400 per annum on cost of sales and services. It is important to note that a change in the cost of sulphur is likely to lead to a change in the price for sulphuric acid as this is a key input cost in the manufacturing of sulphuric acid. Thus, the net impact on earnings of changes in sulphur costs would depend upon changes in sulphuric acid pricing.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

30. CAPITAL MANAGEMENT:

Chemtrade's objective when managing its capital is to safeguard Chemtrade's assets and its ability to continue as a going concern, to meet external capital requirements related to its credit facilities, and to maximize the growth of its business and the returns to its Unitholders. Chemtrade's capital structure is comprised of units, Debentures and long-term debt. The long-term debt does not require payment until December 2026.

The Debentures have maturity dates ranging from September 2025 to June 2028. Chemtrade intends to maintain a flexible capital structure consistent with the objectives stated above and to respond to changes in economic conditions and the risk characteristics of underlying assets. In order to maintain or adjust its capital structure, Chemtrade may purchase units for cancellation, issue new units, raise debt (secured, unsecured, convertible and/or other types of available debt instruments) or refinance existing debt with different characteristics.

Chemtrade utilizes annual capital and operating expenditure budgets to facilitate the management of its capital requirement. These budgets are approved by the Board. Budgets are updated if there are significant changes in fundamental underlying assumptions during a period.

Chemtrade monitors capital using a Net debt to Adjusted EBITDA ratio. Net debt to Adjusted EBITDA ratio is 'Net debt' divided by last twelve months (LTM) Adjusted EBITDA. Chemtrade includes within Net debt, long-term debt, Debentures, lease liabilities, less cash and cash equivalents. Chemtrade monitors Net debt to Adjusted EBITDA as a part of liquidity management to sustain future investment in the growth of the business and make decisions about capital.

	Dece	December 31, 2023		ember 31, 2022
Long-term debt ⁽¹⁾ Add (Less):	\$	246,545	\$	370,024
Debentures (1)		425,552		517,365
Long-term lease liabilities		130,583		94,071
Lease liabilities (2)		49,304		45,571
Cash and cash equivalents		(21,524)		(72,569)
Net debt		830,460		954,462
LTM Adjusted EBITDA (3)	\$	502,637	\$	430,868
Net debt to Adjusted EBITDA		1.65		2.22

⁽¹⁾ Principal outstanding amount, see note 23.

⁽²⁾ Presented as current liabilities in the consolidated statements of financial position

⁽³⁾ LTM Adjusted EBITDA represents the last twelve months Adjusted EBITDA.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

30. CAPITAL MANAGEMENT (continued):

Chemtrade is subject to certain covenants on its credit facilities, which include a Net Debt to EBITDA ratio and an Interest Coverage ratio (as all terms are defined in the credit agreement). Chemtrade monitors these ratios and reports them to its lenders on a quarterly basis. As at December 31, 2023 and December 31, 2022, Chemtrade was in compliance with the above covenants.

There were no changes in Chemtrade's approach to managing capital during the year ended December 31, 2023.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

31. RELATED PARTIES:

Key management personnel compensation

Key management personnel is comprised of trustees and the senior leadership team of Chemtrade. Trustees receive compensation in the form of an annual retainer. In addition to their salaries, Chemtrade also provides other benefits to the senior leadership team. One such benefit is the contribution to a post-employment DC plan on their behalf. Once the contribution reaches the limit allowed under the Income Tax Act (Canada), additional contributions are made to a non-registered account. Chemtrade provides a basic contribution of 4% of base salary for plan participants. They can make additional voluntary contributions up to 2% of their base salary, and Chemtrade matches each dollar contributed up to 2% for a total of 6% of base salary. Contributions to the DC plan vest immediately. These plans for the senior leadership team are identical to the plans offered to all employees in the same jurisdiction.

Chemtrade offers a 401(k) plan to employees in the U.S. including key management personnel. The plan is a qualified retirement 401(k) plan, and is self-directed. Participants choose from a range of investment options offered by Securian, who administers the plan. The interest and earnings on the investments held in the 401(k) plan account vary, and depend on the terms and performance of the investments chosen. Employees make voluntary contributions on each pay, and Chemtrade matches the first 6% of eligible earnings subject to legislated government maximums. Chemtade's contributions to the 401(k) plan vest immediately.

The Annual Incentive Compensation ("Annual IC") plan entitles the senior leadership team to annual cash awards based on (i) Chemtrade's success in achieving financial objectives (financial achievement is weighted at 65% of the total annual IC award); and (ii) their individual success in accomplishing personal objectives (weighted at 35% of the total annual IC award) as set out in their objectives for the fiscal year.

The LTIP, as described in note 27, is designed to align the interests of the participants with the interests of Unitholders. It is a cash plan where payment is triggered upon the successful achievement of pre-defined performance criteria. Each year the Compensation and Corporate Governance Committee of the Board determines the performance period over which performance will be measured. The annual LTIP awards granted have been based on a three-year performance period and the awards vest at the end of the three-year period. The value of this compensation is re-measured at each reporting period based upon changes in the fair value of the awards.

Certain members of the senior leadership team are subject to a mutual term of notice upon termination of employment without cause; they are entitled to termination benefits of 12 to 18 months gross salary. In addition they are entitled to either their target annual IC or a value based on the most recently completed financial year.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

31. RELATED PARTIES (continued):

Chemtrade has in place a deferred unit compensation plan for its non-management trustees, pursuant to which the trustees can elect to take all or a portion of their compensation in the form of deferred units of Chemtrade, with the remainder as a cash payment. Currently, the trustees are required to take 50% of their compensation in the form of deferred units of Chemtrade.

As at December 31, 2023, the market value of these deferred units, which is included in trade and other payables was \$5,771 (2022 - \$5,234).

The key management personnel compensation expense including retirements costs, which is recorded in comprehensive income, is as follows:

	2023	2022
Short-term compensation	\$ 10,449	\$ 9,919
LTIP	10,999	10,489
	\$ 21,448	\$ 20,408

Investment in a Joint Venture

Transactions related to the investment in a joint venture are in note 17.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES:

The accounting policies set out below have been applied consistently by Chemtrade's entities to all periods presented in these consolidated financial statements.

In addition, Chemtrade adopted *Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2)* from January 1, 2023. The amendments require the disclosure of 'material', rather than 'significant', accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies, assisting entities to provide useful, entity-specific accounting policy information that users need to understand other information in the financial statements. Management reviewed the accounting policies and made updates to the information disclosed in this note (2022: Significant accounting policies) in certain instances in line with the amendments. Although the amendments did not result in any changes to the accounting policies themselves, they impacted the accounting policy information in certain instances.

Set out below is an index of the material accounting policies, the details of which are available on the pages that follow:

(a)	Basis of consolidation	65
(b)	Segment reporting	66
(c)	Revenue recognition	66
(d)	Income tax	67
(e)	Inventories	67
(f)	Property, plant and equipment	68
(g)	Leases	69
(h)	Intangible assets	70
(i)	Impairment	71
(j)	Provisions	73
(k)	Employee benefits	74
(1)	Financial Instruments	75

(a) Basis of consolidation

The consolidated financial statements include the financial statements of Chemtrade, its controlled subsidiaries and equity accounted investments, including joint ventures. Control is achieved when Chemtrade has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(b) Segment reporting

A reportable segment is a component of Chemtrade that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of Chemtrade's other components. All operating segments' operating results are reviewed regularly by Chemtrade's CEO to make decisions about resources to be allocated to each segment and assess its performance, and for which discrete financial information is available.

(c) Revenue recognition

(i) Sale of products:

Revenue from the sale of products in the course of ordinary activities is measured and recorded at the most likely amount of consideration expected to be received, net of returns, trade discounts and volume rebates. If it is probable that discounts will be granted and the amount can be measured reliably, then the discount is recognized as a reduction of revenue as the sales are recognized.

Revenue from the sale of products are recognized when control is passed to the customer according to the terms of the contract, which could be upon shipment of goods or when the product reaches the customer site. In certain cases, customers will pick up the products at Chemtrade's plants and Chemtrade will recognize revenues when the product is picked up.

For products sold to pipeline customers, revenue is recognized when the product crosses the property line through the pipeline. This is the point where the product is considered delivered and control of the product transfers to the customer.

(ii) Processing services:

Chemtrade provides processing services to customers that are continuous and ongoing in nature. Generally, processing services are provided for a specified period of time and are not based on volumes or the completion of specific milestones. Therefore, revenue for processing services are recorded over time.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(d) Income tax

Income tax expense is comprised of current and deferred tax. Current tax and deferred tax are recognized in earnings except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income.

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

(e) Inventories

Finished goods inventory is valued at the lower of average cost and net realizable value. Average cost includes all costs of purchase, costs of conversion and other costs incurred to bring inventories to their present location and condition. Costs of conversion include a systematic allocation of fixed and variable production overheads that are incurred in converting materials into finished goods. The allocation of fixed production overheads is based on normal production capacity. Raw material inventory and operating supplies are recorded at the lower of cost determined on a first-in, first-out basis, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(f) Property, plant and equipment

(i) Recognition and measurement:

Items of PPE are measured at cost less accumulated depreciation and accumulated impairment losses.

Parts of an item of PPE having different useful lives, are accounted for as separate items (major components) of PPE.

(ii) Depreciation:

Depreciation is recognized in comprehensive income on a straight-line basis over the estimated useful life of each part of an item of PPE, since this most closely reflects the expected pattern of consumption of the future economic resources embodied in the asset. Land is not depreciated.

The estimated useful lives for the current and comparative periods of plant and equipment are as follows:

Building 5 - 40 years
 Equipment 5 - 40 years
 Furniture and other 3 - 10 years

Facilities and equipment under construction do not begin to be depreciated until substantially complete and ready for productive use.

Depreciation methods, useful lives and residual values are reviewed at each financial year end and adjusted if appropriate.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(g) Leases

Chemtrade leases various assets that include rail cars, private fleet, real estate, vehicles and other heavy-duty machinery and equipment to conduct its daily operations.

Chemtrade assesses whether a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration.

(i) As a lessee

At inception or on reassessment of a contract that contains a lease component in which Chemtrade is a lessee, Chemtrade allocates the consideration in the contract to each lease and non-lease component on the basis of their relative stand-alone prices. However, for certain leases where it is a lessee, Chemtrade has elected not to separate non-lease components and will instead account for the lease and non-lease components as a single lease component.

Chemtrade recognizes ROU assets and lease liabilities for most leases. Chemtrade applies recognition exemptions for short-term leases (i.e. leases with terms less than 12 months or entered into on a month-to-month basis) and leases that are considered to be low-dollar value leases. Short-term and low-dollar value leases are directly recorded in profit or loss.

Chemtrade recognizes an ROU asset and a lease liability at the lease commencement date. The ROU asset is initially measured at cost. Subsequent to initial recognition, the ROU asset is measured at cost less any accumulated depreciation and impairment losses, and adjusted for certain remeasurements of the lease liability. In comparison, the lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Chemtrade's incremental borrowing rate is used. Generally, Chemtrade uses its incremental borrowing rate as the discount rate. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

Chemtrade depreciates the ROU asset on a straight-line basis over the lease term, unless Chemtrade expects to obtain ownership of the leased asset at the end of the lease.

If Chemtrade expects to obtain ownership of the leased asset at the end of the lease, Chemtrade depreciates the ROU asset over the underlying asset's estimated useful life.

(ii) As a lessor

Chemtrade assesses the classification of a sub-lease with reference to the ROU asset, not the underlying asset.

(h) Intangible assets

(i) Goodwill:

Goodwill arising on the acquisition of business is allocated as of the date of the business combination to Chemtrade's CGUs and CGU groups that are expected to benefit from the synergies of the business combination.

(ii) Other intangible assets:

Other intangible assets include the estimated fair value, based on discounted cash flows, at the date of acquisition of long-term customer relationships.

(iii) Amortization of intangibles:

Amortization of intangible assets, excluding goodwill, is calculated over the estimated useful life upon recognition of the asset. Amortization is recognized in comprehensive income on a straight-line basis over the estimated useful lives of intangible assets, from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic resources embodied in the assets. The estimated useful lives for the current and comparative period are as follows:

Customer relationships 10 - 16 years

Other 5 - 10 years

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(i) Impairment

(i) Trade and other receivables:

In relation to trade and other receivables, a provision for impairment is made and an impairment loss is recognized in comprehensive income when there is objective evidence (such as the probability of insolvency or significant financial difficulties of the debtor) that Chemtrade will not be able to collect all of the amounts due under the original payment terms of the invoice. This analysis is performed using a forward-looking "expected credit loss" model under IFRS 9. The carrying amount of the receivable is reduced through use of an allowance account for expected credit losses. Impaired debts are written off against the allowance account when they are assessed as uncollectible. Any subsequent reversal of an impairment loss is recognized in comprehensive income.

(ii) Goodwill:

Chemtrade performs a goodwill impairment test on an annual basis or more frequently when events or changes in circumstances indicate that the carrying amount of a CGU or CGU group likely exceeds its recoverable amount.

Goodwill is not amortized, however Chemtrade performs its annual test for goodwill impairment in the fourth quarter of each fiscal year.

Valuation techniques

The recoverable amount of each CGU or CGU group is based on the higher of its value in use and its fair value less costs to sell. The values assigned to the key assumptions represent management's assessment of future trends in the industry and are based on both external sources and internal sources. An impairment loss is recognized immediately in comprehensive income if the recoverable amount of the CGU or CGU group is estimated to be less than its carrying amount. Any impairment loss on goodwill that is recognized cannot be reversed.

Value in use approach

The value in use approach is predicated upon the value of the future cash flows that a business will generate in future periods. The discounted cash flow method is used which involves projecting cash flows and converting them into a present value equivalent through discounting. The discounting process uses a rate of return that is commensurate with the risks associated with the business or asset and the time value of money. This approach requires assumptions about forecast operating margins, maintenance and other capital expenditures, terminal growth rates and discount rates.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

The following is a description of significant assumptions in obtaining the value in use:

, ,	Chemtrade forecasts operating margins and maintenance and other capital expenditures based on financial budgets, past experience, future growth trends such as gross domestic product ("GDP") growth and inflation, associated economic risk assumptions and estimates of achieving key operating initiatives, covering a five year period.
Terminal Growth Rates	Subsequent to the five year forecast period, Chemtrade applies a terminal growth rate. The terminal growth rate is based on estimated long-term GDP growth and inflation in the markets in which Chemtrade operates.
Discount rates	Chemtrade assumes a pre-tax discount rate in order to calculate the present value of its projected cash flows. The discount rate represents a weighted average cost of capital ("WACC"). The WACC is an estimate of the overall required rate of return on an investment for both debt and equity owners and serves as the basis for developing an appropriate discount rate.

Fair value less costs to sell approach

Fair value less costs to sell is the amount obtainable from the sale of a CGU or CGU group in an arm's length transaction between knowledgeable, willing parties, less the costs of disposal. The estimated market price is based on a historical multiplier based on earnings before interest, taxes, depreciation and amortization and market capitalization.

(iii) Other non-financial assets carried at amortized cost:

If there is objective evidence that an impairment loss on a non-financial asset carried at amortized cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and its recoverable amount. The carrying amount of the non-financial asset is then reduced by the amount of the impairment and the loss is recognized in comprehensive income. If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss is reversed to the extent that the carrying value of the non-financial asset does not exceed the amortized cost had the impairment not been recognized.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(j) Provisions

A provision is recognized if, as a result of a past event, Chemtrade has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic resources will be required to settle the obligation.

The following is a description of various provisions:

Environmental and Decommissioning liabilities

A provision for environmental liabilities is recorded based on current interpretation of environmental laws and regulations when it is probable that a liability has been incurred and the amount of such a liability can be reliably estimated.

Chemtrade recognizes provisions for statutory, contractual, constructive or legal obligations associated with decommissioning of Chemtrade's plants. The fair value of estimated decommissioning liabilities recognized when identified and a reasonable estimate of fair value can be made. A decommissioning asset equal to the estimated fair value of the decommissioning liability is capitalized as part of the cost of the related long-lived asset. The decommissioning asset is depreciated over the asset's estimated useful life and included in cost of sales and services. Increases in the decommissioning liabilities resulting from the passage of time are recorded as accretion of the decommissioning liabilities.

Legal provisions

Provisions for legal claims are measured at the present value of the expenditure expected to be required to settle the obligation using a pre-tax discount rate that reflects the current market assessment of the time value of money and the risks specific to the obligation.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(k) Employee benefits

(i) Defined contribution plans:

DC plan is a post-employment benefit plan under which an Chemtrade pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to DC plans are recognized as an employee benefit expense in comprehensive income in the periods during which services are rendered by employees.

(ii) Defined benefit plans:

A defined benefit pension plan is a post-employment benefit plan other than a DC plan. Chemtrade's net obligation in respect of defined benefit plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods. That benefit is then discounted to determine its present value and the fair value of any plan assets are deducted. The discount rate is the yield at the reporting date on high quality bonds that have maturity dates approximating the terms of Chemtrade's obligations and that are denominated in the same currency in which the benefits are expected to be paid. The calculation is performed annually by a qualified actuary using the projected unit credit method.

Chemtrade deducts the fair values of plan assets from the defined benefit plan obligations to arrive at the net defined benefit plan obligations (assets). For plans that result in a net defined benefit asset, the recognized asset is limited to the present value of economic benefits available in the form of future refunds from the plan or reductions in future contributions to the plan ("asset ceiling"). If it is anticipated that Chemtrade will not be able to recover the value of the net defined asset, after considering minimum funding requirements for future service, it reduces the net defined benefit asset to the amount of the asset ceiling. When the payment in the future of minimum funding requirements related to the past service would result in a net defined surplus or an increase in a surplus, the minimum funding requirements are recognized as a liability to the extent that the surplus would not be fully available as a refund or a reduction in future contributions.

Chemtrade recognizes all actuarial gains and losses, the effect of the asset ceiling (if applicable) and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability) arising from defined benefit plans immediately in other comprehensive income, and reports them in deficit. Depending on the plan, expenses such as plan amendments, current service costs and administration costs are recorded in either cost of sales or selling and administrative expenses within comprehensive income. The interest costs are recorded in net finance costs within comprehensive income.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(iii) Multi-employer plan:

Chemtrade participates in a multi-employer pension plan, which is accounted for as a DC plan. Chemtrade does not administer this plan but rather the administration and the investment of these assets are controlled by a board of trustees consisting of union and employer representatives. Chemtrade's responsibility to make contributions to this plan is established pursuant to its collective agreements.

(iv) Share-based compensation:

Chemtrade operates a LTIP which grants cash awards based on certain criteria. These awards are accounted for as liabilities with the value of these liabilities being remeasured at each reporting period, based upon changes in the fair value of the awards. Any gains or losses on re-measurement are recorded in selling and administrative expenses.

(I) Financial instruments

(i) Non-derivative financial assets:

Recognition and initial measurement

Chemtrade's non-derivative financial assets are comprised of trade and other receivables and cash and cash equivalents. Chemtrade initially recognizes financial assets measured at amortized cost at fair value on the date that they are originated. All other financial assets (including assets measured at fair value through profit or loss) are recognized at fair value on the trade date at which Chemtrade becomes a party to the contractual provisions of the instrument.

Trade and other receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition these financial assets are measured at amortized cost using the effective interest method, less any net impairment for estimated expected credit losses.

Chemtrade de-recognizes the trade receivables sold under its receivables purchase facility when all the risks and rewards of ownership of the receivable are transferred substantially. The balances presented within trade and other receivables in the consolidated statements of financial position exclude the receivables transferred.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

Classification and subsequent measurement

Chemtrade de-recognizes a financial asset when the contractual rights to the cash flows from the asset expire. Financial assets and liabilities are offset and the net amount presented in the consolidated statements of financial position when Chemtrade has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

(ii) Non-derivative financial liabilities:

Recognition and initial measurement

Chemtrade's non-derivative financial liabilities include trade and other payables, distributions payable, long-term debt and convertible unsecured subordinated debentures. Chemtrade initially recognizes long-term debt at fair value on the date that they are originated.

The convertible unsecured subordinated debentures are recognized initially at fair value. Transaction costs related to the convertible unsecured subordinated debentures are expensed as incurred.

Subsequent measurement

Chemtrade de-recognizes a financial liability when its contractual obligations are discharged, cancelled or expired. Financial assets and liabilities are offset and the net amount presented in the consolidated statements of financial position when Chemtrade has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

The convertible unsecured subordinated debentures are measured at fair value at each period end date with the changes recorded in comprehensive income. Any changes in the fair value due to Chemtrade's own credit risk are presented in other comprehensive income rather than net earnings.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(iii) Units:

The Fund units meet the definition of a financial liability under IFRS as the redemption feature of the Fund units creates an unavoidable contractual obligation to pay cash. The Fund units are considered to be "puttable instruments" because of the redemption feature. IFRS provides a very limited exemption to allow puttable instruments to be presented as equity provided certain criteria are met.

The Fund classifies units as equity because they meet all of the puttable instrument exemption criteria.

Chemtrade recognizes the liabilities for unpaid cash distributions, distributions opted to be reinvested and bonuses thereon at the time such distributions are declared. Liabilities for distributions opted to be reinvested and bonuses thereon are de-recognized when such units are issued to the participants.

(iv) Derivative financial instruments:

Chemtrade holds derivative financial instruments to mitigate its foreign currency, unit price and interest rate risk exposures. Embedded derivatives are separated from the host contract and accounted for separately if the economic characteristics and risks of the host contract and the embedded derivative are not closely related.

Derivatives are recognized initially at fair value with attributable transaction costs recognized in comprehensive income as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognized immediately in comprehensive income, except for derivatives designated as cash flow hedges as noted below.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(v) Hedging:

On initial designation of the hedge, Chemtrade formally documents the relationship between the hedging instruments and hedged items, including the risk management objectives and strategy in undertaking the hedge transaction, together with the methods that will be used to assess the effectiveness of the hedging relationship. Chemtrade makes an assessment, both at the inception of the hedge relationship as well as on an ongoing basis, whether the hedging instruments are expected to be "highly effective" in offsetting the changes in the fair value or cash flows of the respective hedged items during the period for which the hedge is designated, and whether the actual results of each hedge are within a range of 80-125 percent. For a forecast transaction to be considered a cash flow hedge, the transaction should be highly probable to occur and should present an exposure to variations in cash flows that could ultimately affect reported earnings.

Cash flow hedges

When a derivative is designated as the hedging instrument in a hedge of the variability in cash flows attributable to a particular risk associated with a recognized asset or liability or a highly probable forecast transaction that could affect earnings, the effective portion of changes in the fair value of the derivative that is designated and qualify as cash flow hedge is recognized in accumulated other comprehensive income. The amount recognized in other comprehensive income is removed and included in earnings in the same period as the hedged cash flows affect earnings under the same line item in the consolidated statement of comprehensive income as the hedged item. Any ineffective portion of changes in the fair value of the derivative is recognized immediately in earnings.

If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated, exercised, or the designation is revoked, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in other comprehensive income and presented in unrealized gains/losses on cash flow hedges in equity remains there until the forecast transaction affects earnings.

IFRS 9 accounting policy choice for hedge accounting

IFRS 9 includes an accounting policy choice between deferring the adoption of the new hedge accounting standards under IFRS 9 and continuing with the IAS 39 hedge accounting standards. Chemtrade has decided to continue to apply IAS 39 hedge accounting standards.

Notes to Consolidated Financial Statements (In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(m) Standards and interpretations adopted during the period:

Chemtrade adopted the following accounting amendments that were effective for its interim and annual consolidated financial statements beginning January 1, 2023. The adoption of these standards have not had a material impact on its financial results:

- IFRS 17, Insurance Contracts, a replacement of IFRS 4, Insurance Contracts, that aims to provide consistency in the application of accounting for insurance contracts.
- Amendments to IAS 1, Presentation of Financial Statements Disclosure of Accounting Policies, requiring entities to disclose material, instead of significant, accounting policy information.
- Amendments to IAS 8, Accounting Policies Changes in Accounting Estimates and Errors, clarifying the definition of "accounting policies" and "accounting estimates".
- Amendments to IAS 12, Income Taxes Deferred Tax related to Assets and Liabilities arising from a Single Transaction, narrowing the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offsetting temporary differences (effective for annual periods beginning on or after January 1, 2023). These amendments do not have any impact on Chemtrade's consolidated financial statements.
- Amendments to IAS 12, Income Taxes International Tax Reform Pillar Two Model Rules, addressing concerns around the accounting for the global minimum top-up tax under the OECD's Pillar Two model rules. A mandatory temporary exception to the accounting for deferred taxes arising from the jurisdictional implementation of Pillar Two model rules is introduced (effective retrospectively and immediately upon issuance of the amendments in May 2023), as well as additional disclosure requirements about Pillar Two income tax exposure (effective for annual periods beginning on or after January 1, 2023). Chemtrade has applied the mandatory deferred tax accounting relief and added the required disclosures under Note 8(g) of the consolidated financial statements.

Notes to Consolidated Financial Statements
(In thousands of Canadian dollars, except per unit amounts)

Year ended December 31, 2023 and 2022

32. MATERIAL ACCOUNTING POLICIES (continued):

(n) Standards and interpretations not yet adopted:

The IASB has issued the following new standards and amendments to existing standards that will become effective in future years.

- Amendments to IAS 1, Presentation of Financial Statements Classification of Liabilities as Current or Non-current, clarifying requirements for the classification of liabilities as non-current (effective for annual periods beginning on or after January 1, 2024).
- Amendments to IAS 7 and IFRS 7, Supplier Finance Arrangements, specifying the
 disclosure requirements to enhance the current requirements, which are intended
 to assist users of financial statements in understanding the effects of supplier
 finance arrangements on an entity's liabilities, cash flows and exposure to liquidity
 risk (effective for annual periods beginning on or after January 1, 2024).
- Amendments to IFRS 10 and IAS 28, Sale or Contribution of Assets between an Investor and its Associate or Joint Venture, addressing the conflict in dealing with the sale or contribution of assets between an investor and its associate or joint venture (deferred indefinitely with an option of early adoption).
- Amendments to IFRS 16, Lease liability in a Sale and Leaseback, specifying how a seller-lessee accounts for variable lease payments that arise in a sale-andleaseback transaction (effective for annual periods beginning on or after January 1, 2024).
- Amendments to IAS 21, Lack of exchangeability, specifies how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking (effective for annual periods beginning on or after January 1, 2025).

While Chemtrade is assessing the impacts, if any, the amendments to existing standards will have on its consolidated financial statements, the amendments to IAS 1, noted above, will impact the presentation of its Debentures. The amendments remove an exception related to the requirement for the unconditional right to defer settlement for more than twelve months for equity settled liabilities that permitted classification as non-current liabilities. Chemtrade does not have an unconditional right to defer the settlement of its Debentures upon conversion into units by the debenture holder nor does it classify the conversion option as equity. As a result, the Debentures will be presented as current liabilities in the Consolidated Statements of Financial Position effective January 1, 2024. While these will be presented as current liabilities, debenture holders do not have the right to demand their repayment prior to maturity, which for all the outstanding series is more than twelve months in the future.